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ABSTRACT 
 
 
 Cardiovascular diseases (CVDs) are the leading cause of death globally. An 
estimated 17.9 million people died from CVDs in 2016, with ~840,000 of them in the 
United States alone. Traditional risk factors, such as smoking, hypertension, and diabetes, 
are well discussed. In recent years, chronic kidney disease (CKD) has emerged as a risk 
factor of equal importance. Patients with mild-to-moderate CKD are much more likely to 
develop and die from CVDs than progress to end-stage renal failure.  Vascular calcification 
(VC), typical in aging, several genetic and metabolic disorders, is now recognized as a 
strong and independent predictor of cardiovascular events and mortality, not only in 
diabetic and CKD patients, even in the general population. VC is classified into two distinct 
types based on location in the vessel wall; intimal and medial. Elastin-associated medial 
arterial calcification (CKD) is more specific to CKD and contributes significantly to 
cardiovascular mortality in these patients. It is responsible for loss of vessel elasticity, 
increased arterial stiffness, increased pulse pressures and systolic blood pressure, and left 
ventricular hypertrophy ultimately causing arrhythmias and heart failure.  
 Current clinical practice is mostly focused on prevention and retardation of VC 
progression. Unfortunately, most patients with CKD remain underdiagnosed, and those 
diagnosed have already heavily calcified vessels. As such, they are undertreated since 
preventative strategies no longer work at this stage. Unfortunately, there is no FDA-
approved treatment available that reverses calcification in countless CKD patients. A 
treatment strategy which promotes resorption of calcified lesions, while simultaneously 
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avoiding demineralization from normally calcified tissues (i.e., bones and teeth) remains 
an urgent health care need. Chelating agents bind to metal cations, can dissolve and “wash 
away” calcium deposits if delivered in close proximity to the calcification sites.  
This work was undertaken to see if we can develop targeted therapies to deliver chelating 
agents to vascular calcification sites. Amongst chelating agents known for their affinity to 
Calcium ions (Ca2+), we found that EDTA chelates Ca2+ from hydroxyapatite better than 
others. In our laboratory, we have developed a unique targeting mechanism by using 
nanoparticles to deliver chelating agents and other drugs to degraded elastin, a 
characteristic feature of VC. We take this approach forward in clinically relevant animal 
models of CKD.  
 First, we tested the targeted nanoparticle-based EDTA chelation therapy in a rat 
model of adenine-induced renal failure. The targeted nanoparticles delivered EDTA at the 
sites of vascular calcification and reversed mineral deposition without any side effects. 
Furthermore, we validated the adenine-CKD model in mice to monitor MAC in vivo and 
explore the phenotypic and functional alterations associated with it. We were able to target 
our nanoparticles to calcified arteries in these mice. The mouse model will help us to test 
whether our EDTA chelation therapy tangibly improves arterial function by restoring 
vascular health. Lastly, we investigated the possibility of using an ex vivo organ culture 
model of VC as a simpler, and relatively easier model to assess if EDTA chelation therapy 
promotes vessel homeostasis. The work presented here represents another major step 
forward towards the development of targeted EDTA chelation therapy as an 
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unconventional therapeutic approach to reverse pathological calcifications in CKD 
patients. 
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1 INTRODUCTION 
 
 Cardiovascular diseases (CVDs) refer to several types of conditions that affect the 
cardiovascular system – heart and blood vessels. CVDs remain the leading cause of death, 
being responsible for ~17.9 (31%) million deaths globally, and 840,000 (1 in 3) deaths in 
the United States alone [1, 2].  CVD is an umbrella term for many diseases, including blood 
vessel disease, heart valve diseases, heart rhythm problems, heart muscle diseases, and 
congenital heart diseases, among others. CVDs are often caused by key risk factors such 
as high blood pressure, high cholesterol, and habitual smoking and at least one of these risk 
factors are present in about half (49%) of the American population [3]. Certain medical 
conditions and poor lifestyle choices which are also considered as risk factors include age, 
sex, physical inactivity, excessive alcohol use, unhealthy diet, obesity, genetic 
predisposition and family history of CVDs, diabetes mellitus and chronic kidney disease 
(CKD) [4-6]. 
 CKD, also known as chronic renal failure (CRF) is a condition characterized by 
gradual damage to and loss of kidney function over time. As the primary function of the 
kidneys is to filter extra water and wastes out of our blood, damage to kidneys causes 
wastes to build up in the body resulting in complications such as high blood pressure, 
anemia, weakening of bones, poor nutritional health, etc. The two major causes of CKD 
are diabetes and high blood pressure, being responsible for up to 2/3rd of cases. Other 
diseases and conditions that cause CKD include glomerulo nephritis, polycystic kidney 
disease, lupus, prolonged obstruction of the urinary tract, vesicoureteral reflux, and more. 
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Since CKD and CVDs share two major risk factors – diabetes and high blood pressure – 
patients with CKD are a group at high risk for developing CVD and cardiovascular events 
[5]. Concomitantly, heart diseases represent the most common cause of death amongst 
people with CKD and undergoing dialysis. The prevalence and burden of CVD only rises 
with declining kidney function. 
 Ectopic calcification has been observed in many CVDs and is recognized as a 
contributing risk factor for cardiovascular events including heart failure, pulmonary 
hypertension, and even death in CKD patients. Based on location, calcifications in CKD 
can be classified into calcifications of vessels viz. atherosclerotic intimal calcification 
(AIC) and medial arterial calcification in large and elastic arteries (MAC), calcification of 
heart valves and calcific uremic arteriolopathy (CUA). CKD patients may develop both 
types of vascular calcifications, elastin-associated MAC is more specific to CKD; In fact, 
in pediatric patients, it is the only form of vessel calcification seen.  
 Current treatment methods have been limited to preventing and retarding the 
progression of calcification. Notably, as yet, there is no consensus about screening for and 
intervening to retard the progress of VC and even the most dramatic interventions such as 
intense dialyses and renal replacement, make it clear that manifested vessel calcification 
cannot be removed. A few options to treat vascular calcifications are surgical methods like 
directional atherectomy to physically remove the mineral deposits and placement of stent 
grafts to keep the artery open [7, 8]. They are quite invasive and detrimental. A large 
number of patients as such remain underdiagnosed and those diagnosed have already 
calcified arteries. Therefore, they remain undertreated since preventative strategies can no 
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longer work at this stage. There is a dire need of an alternative pharmacological approach 
that promotes reversal of VC by resorption of calcified lesions without detrimental 
demineralization in normal tissues (i.e., bones and teeth).   
 Chelation therapy has been long investigated for reversal of atherosclerotic 
calcification. This process typically involves an injection of disodium ethylene diamine 
tetraacetic acid (EDTA), a synthetic chemical that binds, or chelates ionic calcium, trace 
elements, and other divalent cations [9]. Systemic chelation therapy requires high dosages 
of EDTA to be injected, which may result in unwanted side effects such as hypocalcemia, 
renal toxicity, and loss of mineral from bone [10, 11]. In our laboratory, we have developed 
a unique method to deliver chelating agents, and other therapeutics, in a site-specific 
manner to vascular calcification sites through targeted nanoparticles (NPs). Further, we 
have shown that such targeted delivery of EDTA through use of albumin NPs to a calcified 
site, reverses experimentally created vessel calcification while avoiding untoward side 
effects of systemic therapy.  
 In this dissertation, we take this approach forward in a clinically relevant animal 
model of CKD. We have studied the efficacy of targeted EDTA chelation therapy in a 
dietary adenine model of renal failure in rats. We also explored the feasibility of using 
targeted EDTA chelation therapy in a mouse model of dietary adenine which would serve 
as an aid in the near future to investigate if reversal of arterial calcification improves 
vascular homeostasis through the use of cell-lineage tracing. Additionally, we examined if 
removal of calcification by EDTA chelation therapy can reverse the associated phenotypic 
changes of vascular smooth muscle cells (VSMCs) in an organ culture model of porcine 
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carotid arteries. Overall, our goal was to present targeted EDTA chelation as an excellent 
alternative therapeutic approach to reverse MAC clinically.  
 The dissertation is organized as follows:  
• In Chapter 2, we present a comprehensive review of: 
→ Cardiovascular System: Cardiovascular diseases, cardiovascular 
system, and structure of the aortic wall. 
→ Elastin: Structure, function, ultrastructure, mechanism of elastin 
synthesis and elastic fiber assembly, and elastin degradation in disease. 
→ CKD: Definition, classifications, consequences, and cardiovascular 
complications in CKD. 
→ VC: Types, mechanisms, and current treatment strategies. 
→ Animal models of VC: In vivo studies with animal models of VC, CKD 
and MAC, and adenine-induced CKD model of VC. 
→ Chelation Therapy: Definition, history of chelation therapy, types of 
chelating agents used, EDTA chelation therapy, clinical trials with 
EDTA chelation therapy.  
→ Targeted EDTA chelation therapy: Nanoparticles as drug delivery 
agents, albumin nanoparticles, targeting of albumin nanoparticles to 
degraded elastin in calcification. 
• Chapter 3 provides rationale for this research and specific aims designed for 
this project. 
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• In Chapter 4, we compare three different chelating agents – EDTA, EGTA, 
and BAPTA to deduce the best chelator for use in targeted chelation therapy 
• In Chapter 5, we discuss whether EDTA, a chelating agent, loaded and 
elastin-antibody conjugated nanoparticles can be targeted to sites of elastin-specific 
medial arterial calcification for its reversal in a rat chronic kidney disease model.  
• In Chapter 6, we demonstrate targeting of elastin-antibody conjugated 
albumin nanoparticles to sites of medial arterial calcification in a mouse adenine 
model of CKD-induced calcification. Monitoring of disease progression in vivo and 
VSMC cell status were explored for the potential use of this model to investigate 
whether reversal of MAC through targeted EDTA chelation therapy can restore 
vascular homeostasis. 
• In Chapter 7 we explore the feasibility of an ex vivo organ culture model of 
porcine carotid arteries to better understand the mechanism of VC and direction of 
VSMC before and after treatment with EDTA-loaded NPs. The ex vivo model may 
serve as a bridge between cell culture and extensive animal models currently in use 
to provide complementary information about intrinsic mechanisms and treatment 
of VC.  
• Chapter 8 summarizes and lists conclusions from the present research and 
provide future recommendations to take this research forward and take major steps 
towards clinical translation of targeted EDTA chelation therapy for permanent 
reversal of VC. 
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2 REVIEW OF LITERATURE 
 
 Cardiovascular diseases 
 Cardiovascular diseases (CVDs) are the number one cause of death globally; more 
people die annually from CVDs than of any other cause. An estimated 17.9 million people 
died globally from CVDs in 2016, representing approximately 30% of all registered deaths 
[1]. Out of the 17 million premature deaths due to non-communicable diseases in 2015, 
82% are in low- and middle-income countries, and 37% of them are caused by CVDs [2]. 
In the United States alone, CVDs have remained the leading cause of death, responsible 
for as many as 840, 000 deaths in 2016. The annual total cost of CVDs in the US has been 
estimated at $351.2 billion in 2014-15 [12].  
 The term CVDs describe a range of conditions that affect the cardiovascular system 
– heart and blood vessels. They are grouped into disorders of the blood vessels, such as 
coronary artery disease, cerebrovascular disease, peripheral arterial disease, arterial 
calcification, abdominal aortic aneurysms (AAAs), deep vein thrombosis and pulmonary 
embolism; disorders of the heart structure and muscle, including congenital heart disease, 
rheumatic heart disease, carditis and cardiomyopathy; problems with heart rhythms known 
as arrhythmia; and disease of the heart valves, like calcification of the heart valves, valve 
prolapse and stenosis.  
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Figure 2-1: Global map, age-standardized death rate of CVD in 2015 [13]. 
 
Figure 2-2: Heart disease death rates across the US [14]. 
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Figure 2-3: Types of Cardiovascular Diseases [15]. 
 
 Risk factors for CVDs are classified as non-modifiable and modifiable. Non-
modifiable risk factors are age, gender, ethnic background, socioeconomic status, and 
familial history of the disease. Physical inactivity, excessive tobacco use and alcohol 
consumption, unhealthy diet resulting in high cholesterol levels and obesity, uncontrolled 
blood pressure come under modifiable risk factors [3, 4, 16]. With better lifestyle choices, 
modifiable risk factors can be kept under check and reduce chances of having CVDs. Heart 
failure is the most common, costly, and potentially fatal outcome of many of the CVDs 
[17].  
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 The Cardiovascular System  
 The Cardiovascular System (Figure 1-4), also known as the circulatory system, 
functions to carry blood through vessels to and from all parts of the body. It is a closed 
tubular system in which the blood is propelled by a principal muscular organ called the 
heart. There are two major circuits in the circulatory system, the systemic and the 
pulmonary, both made up of vessels viz., arteries, veins and capillaries [18].   
  
Figure 2-4: The human cardiovascular system (simplified). Red indicates oxygenated 
blood in the arteries, blue indicates deoxygenated blood in veins [18].  
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 A third circuit known as the lymphatic system, whose primary function is to 
transport lymph, is also considered part of the circulation and helps the body to get rid of 
toxins, waste and other unwanted materials.  Blood vessels vary with size and function, 
but all of them possess the same basic structure. Each type of vessel has a lumen -  a hollow 
passageway through which the blood flows and is surrounded by the vessel wall. The vessel 
wall has three layers, or tunics, meaning “coats” in Latin.  
  
Figure 2-5: Structure of Blood Vessels. (a) Arteries,  
(b) veins, and (c) Micrograph showing relative differences in thickness [19].  
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 The deepest layer, tunica intima, is lined by a specialized simple squamous 
epithelium known as endothelium. The middle layer, tunica media, is the thickest of the 
layers in arteries. It is rich in smooth muscle supported by connective tissue mainly made 
up of elastic fibers arranged in circular sheets. The outer layer is the tunica adventitia (this 
is the thickest layer in the veins) and is entirely made of connective tissue primarily 
composed of collagenous fibers and nerves that supply the vessel as well as the nutrient 
capillaries (called vasa vasorum) in the larger blood vessels.   
 Arteries carry blood from the heart to various organs and can be further 
subcategorized by their size. All arteries, as mentioned above have relatively thick walls 
that can withstand the high pressure of blood ejected from the heart. Those closest to the 
heart have the thickest walls, containing a high percentage of elastic fibers throughout the 
wall. These type of arteries are elastic arteries and are typically >10mm in diameter. Further 
from the heart, where the blood surge is stifled, the percentage of elastic fibers decreases, 
and there is increased smooth muscle in the medial layer. These are the muscular arteries 
with a diameter range between 0.1mm and 10mm. Muscular arteries branch to distribute 
blood to a vast network of arterioles.  The transition from artery to arteriole is very gradual, 
with progressive thinning of the wall and decreased lumen size (the diameter of an 
arteriole is <0.5mm).  Overall, the heart forces blood into the arteries, who through their 
elastic recoil, send blood on in pulsating waves. Therefore, it is crucial that the arteries 
possess strong, elastic walls to ensure fast, efficient blood flow in absence of which there 
would be a plethora of vascular complications.  
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 Elastin Structure and Degradation 
 Elastin makes up roughly 50% of the arterial extracellular matrix (ECM) as 
discussed above and is the most prevalent structural protein. Aside from the arteries, elastin 
is present in the ECM of tissues like skin, lungs and renders them elastic properties. With 
a half-life period of 74 years, majority of elastin deposition in the body occurs during 
embryonic stage and early childhood [20, 21]. It rarely undergoes any remodeling and has 
a very low turn-over rate. Synthesis of elastin been well documented in fibroblast cells, 
smooth muscle cells, chondrocytes, and endothelial cells [22-25] 
 Elastin is made up of elastic fibers that have two key components, one amorphous 
and one fibrillary. The amorphous component is extensively cross-linked and comprises 
90% of the mature fiber. The fibrillar component is a collection of microfibrils that are 
roughly 8-16 nm long and rich in acidic glycoproteins [26, 27]. These microfibrils are 
located around the periphery of the amorphous content and contain a number of 
glycoproteins like microfibril-associated glycoproteins (MAGP-1, -2, -3, -4, fibrillins, 
latent TGF-β binding protein (LTBP) and fibulins contribute to anchorage of elastin and 
provide its structural coating [28, 29].  
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Figure 2-6: TEM of cross section of elastin and fibrillin deposited by rat vascular cells in 
culture [30]. 
 
 The primary structure of elastin is mainly composed of hydrophobic amino acids, 
such as glycine and proline [31]. There are a couple of highly conserved peptide sequences 
in the elastin fiber – ‘VPGVG’ and ‘PGVGV’. Due to these recurring amino acid residues 
(XPGX’ where X and X’ are hydrophobic), elastin is a highly hydrophobic protein [32].  
 The cellular production, orientation, assembly, crosslinking, and deposition of 
elastin is a tightly regulated hierarchical process and is not very well understood. 
Tropoelastin, a 72 kDa soluble precursor of mature elastin, is its monomeric form. Human 
tropoelastin is encoded by a single gene (ELN) with multiple isoforms and is present as a 
single copy on the chromosome-7 [33]. Post translational modification of tropoelastin 
results in the mature 60 kDa protein. Tropoelastin gene is expressed during prenatal 
development by smooth muscle cells, endothelial cells, and fibroblasts.  As we age, 
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however, ELN expression decreases dramatically along with decreased elastin production. 
In middle-aged people, elastin production is mostly non-existent, and humans rely on 
elastin deposition that occurs in the womb and very early in life [34].  
  The process of elastogenesis is broadly classified into the following stages: (i) 
tropoelastin synthesis, (ii) coacervation, (iii) microfibrillar deposition, (iv) crosslinking, 
and (v) maturation. In order for a mature elastin fiber to form, tropoelastin molecules must 
interact and crosslink with each other. Fibrillin-1 largely makes up the microfibrils in the 
ECM that anchor the forming elastic fibers.  Lysyl oxidases are a group of five enzymes 
including LOX, and LOXL 1-4, which cross-link tropoelastin and aid the process.  
 
Figure 2-7: Illustration of elastin fiber synthesis and assembly [35]. 
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 Initially, the ELN gene is expressed by cells and tropoelastin molecules are secreted 
into the ECM. These tropoelastin molecules begin to self-aggregate or coacervate due to 
the inherent tendency of tropoelastin to coacervate owing to its excessive hydrophobicity 
[36]. The coacervating tropoelastin molecules form ~1µm spherules and remain attached 
to the cell surface until their deposition on microfibrils. Elastin binding protein (EBP), 
made of a 67 kDa peripheral subunit attached to two membrane-bound proteins of 61 kDa 
and 55 kDa MW, carries tropoelastin molecules to fiber formation sites on the surface of 
the cell.  Tropoelastin initially binds to EBP and forms a stable complex. The 67 kDa 
subunit then loses its affinity for tropoelastin and the membrane-bound protein, when a 
sugar moiety binds to the EBP. This loss of affinity results in tropoelastin being released 
onto growing elastin fibers [26]. The microfibrils in ECM provide a scaffold for directing 
and propagating elastin growth and further coacervation and also recruit LOX enzymes for 
crosslinking [37-39].  
 Eventually, tropoelastin is oxidized by LOX enzymes and is followed by aldol 
condensation and Schiff base reactions among lysyl residues resulting in crosslinking of 
elastin fibers with desmosine and isodesmosine links [40]. The matured elastin produced 
as the final product is very stable and gives the tissues their ability to stretch and recoil 
[41]. This entire process of elastic fiber assembly is illustrated in Figure 1-7.  
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Figure 2-8: Depiction of elastic recoil [42]. 
 
  
 One of the consistent features of many vascular diseases is the fragmentation and 
degradation of elastic lamina. Elastic lamina degradation is witnessed in vascular 
calcification [43, 44], diabetes [45], end-stage renal disease [46, 47], and aortic aneurysm 
[48]. Additionally, vascular proliferative diseases affecting smaller arteries like coronary 
arterial occlusion and atherosclerotic-mediated stenosis share elastin degradation as a 
common pathological feature [49, 50]. In such disease conditions, elastic lamina is 
degraded and the amorphous elastin core protein is exposed. 
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 Chronic Kidney Disease  
Chronic Kidney Disease (CKD) is a broad moniker for heterogeneous disorders 
affecting kidney structure and function. It is a worldwide public health problem with an 
ever-increasing incidence and prevalence, resulting in poor outcomes, and therefore a high 
treatment cost [51]. The National Kidney Foundation (NKF), in 2002, published 15 clinical 
practice guidelines on evaluation, classification, and risk stratification in CKD. The 
definition of CKD has evolved since then, but current international guidelines define this 
condition as decreased kidney function as indicated by glomerular filtration rate (GFR) of 
less than 60 mL/min per 1.73m2, or kidney damage markers, or both, for a minimum of 3 
months [52]. When GFR is found to be less than 15 mL/min per 1.73m2, the patient is 
adjudged to have reached end-stage renal disease (ESRD) at which point the kidney is no 
longer believed to sustain life over the long term. The burden of CKD is substantial; 
According to WHO global health figures, 1.5% of the deaths worldwide were attributed to 
CKD in 2012 and it is further projected that the death rate from CKD will continue to 
increase to reach 14 per 100,000 people by 2030 [53].  CKD is common among adults in 
the US; more than 30 million American adults may have CKD, with its associated diseases 
being the 9th leading cause of death [54]. The two primary causes of CKD are diabetes and 
hypertension, being responsible for 2/3rd of the cases in high- and middle-income countries 
and also low-income countries. Diabetes accounts for 30-50% of all CKD and affects 285 
million (6.4%) adults worldwide, and this number is only expected to increase by 69% in 
high-income countries and 20% in low-income and middle-income countries by 2030.  
Greater than a quarter of the adult worldwide population was estimated to have 
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hypertension in 2000, while this proportion is projected to rise by approximately 60% by 
2025 [55]. Other conditions that affect the kidneys include glomerulonephritis, inherited 
diseases such as polycystic kidney disease, developing malformations, lupus and 
obstructions caused by kidney stones, tumors, or enlarged prostate in men. In developing 
countries, common causes of CKD may also include glomerular and tubulointerstitial 
diseases as a result of infections and exposure to drugs and toxins [56].   
A conceptual model for development, progression, and complications of CKD 
includes antecedents associated with increased risk, disease stages, and complications 
including death. Risks are usually categorized either as susceptibility to kidney disease 
because of sociodemographic and genetic factors, or as exposure to factors which would 
lead to the disease. It is noted that early stages of diseases are often devoid of symptoms 
and detected during assessment for comorbid disorders, and tend to be reversible. Rapidly 
progressive diseases, however, can lead to kidney failure within months. Owing to its 
importance in the pathophysiology of complications, GFR is used to classify CKD into five 
stages: more than 90 mL/min per 1·73 m 2 (stage 1), 60–89 mL/min per 1·73 m 2 (stage 
30–59 mL/min per 1·73 m 2 (stage 3), 15–29 mL/min per 1·73 m 2 (stage 4), and less than 
15 mL/min per 1·73 m 2 (stage 5).  
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Figure 2-9: Conceptual model for chronic kidney disease and its complications [57] 
 
  Kidney failure is traditionally considered as the most serious outcome of CKD. 
When symptoms are severe, they can be treated only through dialysis or in more serious 
cases transplantation. As mentioned above, kidney failure at this stage is known as ESRD. 
However, there are several other consequences of CKD that include not only renal 
dysfunction and progressive renal failure but also complications of decreased kidney 
function and increased risk of cardiovascular disease. Additional complications include 
acute kidney injury, infection, cognitive impairment, and diminished physical function [58-
63]. All these complications contribute to high morbidity and mortality and in general,  
poor quality of life. In patients with CKD, compared to general population, cardiovascular 
diseases (CVDs) are more frequent and severe. It often goes unrecognized and 
undertreated, and it is now increasingly apparent that individuals with various stages of 
CKD are more likely to die of cardiovascular complications than progress to ESRD. As 
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such, these individuals must be viewed as being in the highest risk group for cardiovascular 
disease and mortality [64, 65].  
 Cardiovascular Complications in CKD 
CVD also represents the leading cause of mortality in CKD patients, and its 
prevalence and burden only increase with declining renal function [66, 67].  Cardiovascular 
complications are approximately three times more frequent in patients with CKD than in 
other known cardiovascular risk groups, and mortality is 10-fold more frequent in patients 
on dialysis than age- and sex-matched non-renal populations. As a matter of fact, patients 
with mild to moderate CKD (Stages 1-3 are much more likely to develop and die from 
CVD than progress to ESRD.  Increased cardiovascular risk in CKD patients is partly 
because of traditional risk factors such as diabetes, hypertension, and hyperlipidemia. 
However, associations of reduced kidney function with cardiovascular risk are independent 
of these traditional risk factors, and they fail to adequately explain the observations made 
in these patients.  
Non-traditional kidney-specific risk factors make noteworthy contributions to 
cardiovascular risk in these cases. Some of these non-traditional factors that play a role in 
the association of renal failure and CVD include anemia, hypervolemia, 
hyperphosphatemia, endothelial dysfunction, nitric oxide bioavailability, Asymmetric 
dimethylarginine (ADMA), dyslipidemia, inflammatory and oxidative stress, etc. [68-70]. 
Apart from left ventricular hypertrophy (LVH), which is present very early in the disease 
course even in normotensive CKD patients, structural alterations of the myocardium, as 
well as intra-and extra-cardiac blood vessels are hallmarks of this disease.  
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Cardiovascular calcifications also become highly prevalent as CKD progresses and 
are potent predictors of cardiovascular mortality in these patients [46, 71]. London et al.  
demonstrated that the extent and histoanatomic type of vascular calcification are predictors 
of subsequent mortality [72]. There are four different manifestations of calcifications in 
diseased patients: advanced calcification of the intimal plaques, medial calcification of 
large and elastic arteries, calcification of heart valves and myocardium, and a rare condition 
known as calcific uremic arteriolopathy (also known as calciphylaxis). All four of them are 
distinct yet have overlapping pathological mechanisms [71, 73, 74].  
 
 
Figure 2-10: Types of cardiovascular calcifications. (A) Atherosclerotic calcification. (B) 
Medial calcification. (C) Valvular calcification. (D) Calciphylaxis [75] 
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 Vascular Calcification 
Accelerated vascular calcification is a hallmark of CKD patients and plays a pivotal 
role in the CVD burden and eventual mortality in these patients. In patients with late-stage 
renal disease, the risk of death linearly correlates with an increase in numbers of sites on 
the vasculature affected by calcification; in the aorta, carotid, and femoral arteries [76].   
 
 
Figure 2-11: Probability of all-cause survival according to calcification score [76]  
 
 Types of Vascular Calcification 
Two types of calcification are observed in the vasculature, both of which affect 
patients with long-standing kidney disease, particularly amongst those on dialysis – medial 
arterial calcification (MAC, also known as calcific arteriosclerosis or Monckeberg’s 
sclerosis) and accelerated calcification of intimal plaque (also known as calcific 
atherosclerosis) [71, 77-79].  
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Figure 2-12: Atherosclerotic intimal calcification vs. Medial arterial calcification [80] 
 
Intimal calcification is typically considered the last step in classical atherosclerosis 
and is a multifactorial process involving inflammation, macrophage infiltration, 
dyslipidemia, and advanced glycation end products (AGEs), etc. On the contrary, medial 
calcification is characterized by diffuse mineral deposition circumferentially along or 
within elastic lamellae of the medial layer of the arterial wall. It can occur independently 
or in conjunction with intimal calcification but is more common among the two in CKD or 
diabetic patients [73, 81].  Morphologically, atherosclerotic calcification occurs as 
dispersed, spotty, and patchy deposits of calcium in a matured plaque whereas MAC gives 
a “tram-line” or “railroad track” like appearance as more and more lengths of the arterial 
tree calcify.  
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Intimal calcification results in vessel narrowing and dysfunction, possibly causing 
a thrombotic event eventually. Atherosclerotic plaque burden is higher, and the lesions 
more distinctly calcified in CKD patients compared to normal populations.[82]. MAC, on 
the other hand, contributes to loss in vessel elasticity, increased arterial stiffness resulting 
in increased pulse pressures, increased systolic blood pressure, and LVH ultimately causing 
arrhythmias and heart failure [72]. While patients with CKD can develop both types of VC, 
MAC is more specific to CKD; it is the exclusive form of VC observed in pediatric CKD 
patients.  MAC contributes significantly to cardiovascular mortality in CKD patients [83].  
 
Figure 2-13: Radiographs of intima and media calcification as seen in the pelvis and the 
thigh of CKD patients. (A) Intima calcification is seen as discrete plaques with irregular 
and patchy distribution. (B &C) Media calcification present as a uniform linear railroad 
track. (D) Presence of both, intima and media calcification is reflected as discordances 
[72].  
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 Mechanisms of Vascular Calcification 
 Calcification of arteries in CKD is a catenation of well-orchestrated and tightly 
regulated processes which involve cellular and molecular reprogramming, structural and 
functional changes in arterial cells and ECM. Several studies have described key events 
required for the initiation and promotion of calcification. An imbalance of calcification 
inhibitors and promoters in CKD drives calcification. Loss of inhibitors which tightly 
control spontaneous pathological precipitation of calcium – phosphate crystals, such as 
Matrix Gla-protein (mGP) [84], Fetuin-A [85], Klotho [86], Pyrophosphate  (PPi) [87], 
Osteopontin [88], Osteoprotegerin [89] instigates calcification. Transcription factors such 
as Runt-related transcription factor (RUNX2, also known as Cbfa1) [90], Muscle segment 
homeobox 2 (MSX-2) [91], Bone-morphogenic proteins (BMP-2, 4 and 6), Osteocalcin 
(OCN), Alkaline phosphatase (ALP) [92] etc. which are critical for normal bone 
development, have been identified at sites of human arterial calcification in both general 
and CKD patients [93], in animals and also in vitro. In addition, development of a 
calcifiable ECM, induction of apoptosis and vesicle release accompanied by 
osteogenic/chondrogenic differentiation of vascular smooth muscle cells (VSMCs) are all 
important players which spur active calcification processes [90, 94, 95].  
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Table 1-1: List of inhibitors and promoters of vascular calcification in CKD. 
 
Although a multitude of mechanisms are involved, ectopic, especially vascular, 
calcification in CKD is largely actuated by a dysregulation of mineral metabolism, in 
particular Ca and P. Hyperphosphatemia, a result of reduced renal phosphate clearance in 
combination with increased Ca X P product level are recognized as chief culprits of 
accelerated arterial calcification in CKD patients. Deposition of calcium phosphate salts in 
the media of the arteries occurs on the amorphous elastin that makes up the elastic lamellae. 
It is augmented in the context of elastin degradation by elastases and other such proteases. 
In particular, Matrix metalloproteinases (MMPs) and cathepsins (CTS) have been shown 
to be overexpressed and involved in calcified arteries. MMP-2, MMP-9, CTS-K, and CTS-
L can degrade elastin laminae in the media [96-100].  
 
 
 
Calcification Inhibitors 
 
Calcification Promoters 
 
Matrix Gla-protein   
Fetuin-A 
Klotho 
Pyrophosphate 
Osteopontin 
Osteoprotegerin  
BMP-7 
BMP-2,4 and 6 
Osteocalcin 
Alkaline Phosphatase 
RUNX2 
Oxidative Stress 
MMP2, 3 and 7 
SOX9 
Ca2+ and PO42- 
Apoptosis/Apoptotic bodies 
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Figure 2-14: Mechanism of vascular calcification in chronic kidney disease [94]. 
 
 Current Treatment Strategies  
Therapeutic strategies and inventions that may stabilize and potentially reverse 
vascular calcification may be of immense value to patients with CKD. Most of the 
treatment methods in use have been limited to optimizing and managing the dysregulated 
mineral metabolism and bone turnover diseases, both of which are characteristic to CKD. 
It should be noted here that the strong relationship between progressing renal dysfunction 
and increased presence and severity of VC means that primary prevention may potentially 
have a positive impact on VC. A good number of clinical trials in patients with 
hypertension and normal renal function have shown that anti-hypertensive treatments 
reduce aortic stiffness [101, 102].  Different classes of antihypertensive drugs may have 
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different effects on arterial stiffness. Calcium channel blockers (CCBs), Angiotensin-
converting enzyme inhibitors (ACEi), and Mineralocorticoid receptor antagonists 
(MCRAs) have a beneficial effect in reducing arterial stiffness and central blood pressure. 
The first study in humans to demonstrate an effect of CCBs on VC was a sidearm of the 
Nifedipine Study: Intervention as Goal for Hypertension Therapy (INSIGHT). In this 
particular study, nifedipine was found to inhibit the progression of coronary calcium in a 
sub-group of 201 high-risk hypertensive patients compared to co-amizolide (a diuretic). 
However, the exact clinical message of this study is unclear in the light of INSIGHT results 
which showed comparable effectiveness of nifedipine and co-amizolide in preventing 
overall cardiovascular events [103]. Other studies prior and after have evaluated the effect 
of CCBs for their effect on central blood pressure and arterial stiffness [104, 105]. 
It is now common knowledge that ACEi, Angiotensin receptor blockers (ARBs) 
and Aldosterone antagonists interfere with the Renin-Angiotensin-Aldosterone System 
(RAAS), and confer benefits on vasculature beyond simply controlling the blood pressure. 
The effects of ACE inhibition on coronary plaque progression in humans in relation to its 
calcium content have been investigated in a study named PERSPECTIVE. A substudy of 
the EUROPA trial, PERSPECTIVE tested the effect of perindopril on coronary plaque. 
Only plaques with a calcium score of 0-25% regressed with perindopril in comparison to a 
placebo, but plaques with moderate (25-50%) and high (50-100%) calcification progressed 
equally as in placebo group [106]. In another study with 478 young type I diabetic patients 
having albuminuria, ACEi/ARB treatment significantly lowered CAC progression over 
~2.5 years compared to those without any treatment [107]. In a prospective randomized 
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trial with 31 patients having essential hypertension and LVH, the effects of combined 
therapy of an ARB (Valsartan) and ACEi (Perindopril) were studied and compared with 
those of respective monotherapies. The findings suggested that, compared to respective 
monotherapies, perindopril, and valsartan together exerted greater favorable effects. 
Further, an open randomized trial conducted by Frimodt-Møller M et al. investigated 
whether a more complete inhibition of RAAS by combining ACEi (Enalapril) and ARB 
(candesartan) compared to monotherapy has an additive benefit in CKD patients. They 
found that dual blockade of RAS resulted in additive BP independent reduction in Pulse 
wave velocity (PWV) and arterial stiffness compared to monotherapy [108].  
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Table 2-2: Primary prevention of vascular calcification 
 
 
Treatment 
 
Mechanism of 
Action/Outcome 
References 
 
Primary Prevention – Antihypertensive Drugs 
 
Calcium Channel Blockers 
(CCBs) 
Nifedipine 
 
 
 
 
 
 
Slower progression of 
coronary calcification in 
patients on nifedipine vs. co-
amilozide 
 
 
 
 
 
Motro et al. 2001 [103] 
 
 
 
 
 
Angiotensin-converting 
Enzyme Inhibitors 
(ACEi)/Angiotensin Receptor 
Blockers (ARBs) 
Perindopril 
 
 
 
 
 
 
Perindopril/Valsartan 
 
 
 
 
 
Enalapril/Candesartan 
 
 
 
 
 
Coronary plaques with no or 
little calcium (0-25%) 
regressed on perindopril and 
not in placebo 
 
 
 
ACEi/ARB treatment was 
associated with substantially 
reduced odds of CAC 
progression 
 
 
Dual blockade of the RAAS 
resulted in additive BP 
independent reduction in 
PWV and arterial stiffness in 
CKD patients. 
 
 
 
 
 
 
Bruining et al. 2009 [106] 
 
 
 
 
 
 
Maahs et al. 2006 [107] 
 
 
 
 
 
Frimodt-Møller M et al. 2012 
[108] 
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Beyond primary prevention using antihypertensives, secondary prevention of VC 
by correcting hyperphosphatemia and secondary hyperparathyroidism (sHPT), which are 
universal consequences of renal failure embodies a central clinical approach. This is 
accomplished by oral phosphate binders, active vitamin D compounds, calcimimetics, 
adjusting calcium concentration in the dialysate, and surgical correction of sHPT. It is 
pertinent to note that phosphate control by dietary restriction to 800-1000 mg/day lowered 
urinary phosphate excretion along with a decrease in phosphorus absorption, but the 
regimens are notoriously hard, and there is a tendency to relapse. [109].  
Oral phosphate binders are the mainstay in the management of serum phosphate 
levels in patients undergoing dialysis. These medications bind to phosphate in the gut, 
either by forming an insoluble complex or by binding it into a resin and are usually 
classified as calcium-containing (Calcium acetate, Calcium carbonate, Calcium 
ketoglutarate, etc.) and calcium-free (Magnesium carbonate, Lanthanum carbonate, 
Sevelamer hydrochloride, and Sevelamer carbonate, etc.). Although both kinds of 
phosphate binders are effective at regulating phosphate levels, the calcium-containing 
phosphate binders are hazarded for their concomitant calcium load and its effect on 
vascular calcification [110]. In a randomized study with 200 hemodialysis patients treated 
with either sevelamer or calcium salts for the treatment of hyperphosphatemia, serum 
phosphate was controlled equally with both agents whereas subjects treated with calcium 
experienced significant hypercalcemia and intact Parathyroid hormone (PTH) levels. 
Moreover, both coronary artery and aortic calcification progressed significantly with 
calcium but not with sevelamer (~6 months – 1 year) [111]. A total of 119 patients with no 
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evidence of coronary calcification showed little evidence of disease development over the 
next 18 months, either on calcium-containing phosphate binders or sevelamer. However, 
subjects with a history of at least mild coronary calcification had significant progression at 
6, 12, and 18 months following treatment with those on calcium-containing phosphate 
binders showing rapid progression [112].  Several prospective studies show an evidently 
reduced rate of Coronary artery calcium (CAC) in ESRD patients on sevelamer compared 
with those on calcium carbonate or calcium acetate [113].  
Ameliorating the effects of sHPT is a vital approach to treat disordered bone and 
mineral metabolism. Although high parathyroid hormone itself does not correlate 
positively with and may not cause vascular calcification, its management may help in 
minimizing hypocalcemia. Management of sHPT is achieved by active vitamin D 
compounds, calcimimetics, etc. Vitamin D plays an important role in multiple metabolic 
pathways, including regulation of mineral metabolism. Active vitamin D formulations, or 
vitamin D receptor activators (VDRAs) including calcitriol, alfacalcidiol, doxercalciferol, 
and paracalcitriol have been prescribed in the treatment of sHPT in CKD. Hemodialysis 
and peritoneal dialysis patients who received VDRAs experience better survival outcomes 
than those who do not, regardless of their PTH levels [114]. Calcitriol, alfacalcidiol, and 
doxercalciferol can effectively lower PTH but have the side effect of heightening 
gastrointestinal absorption of Ca and P causing an undesirable load [115]. In a 2-year 
follow up study in dialysis patients, progress of aortic arch calcification was associated 
with higher accumulative doses of alfacalcidiol [116]. Paracalcitriol may preferentially 
target the parathyroid gland while avoiding the gastrointestinal effect and thus is less 
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associated with VC [117]. Nevertheless, more suitably sized randomized controlled trials 
are needed to determine the optimal doses and type of VDRAs to be used in therapy. 
 Calcimimetics are compounds that mimic the effects of Ca in vivo. They can work 
as a treatment for hyperparathyroidism by binding to Calcium sensing receptors (CaSRs) 
in the parathyroid glands. By binding to CaSRs, calcimimetics allosterically modulate them 
to become more sensitive to existing levels of circulating Ca, and they, in turn, suppress 
excess secretion of PTH. The only significant randomized study to assess the effects of 
calcimimetics is the ADVANCE study with CINACALCET which showed that along with 
the use of VDRA therapy, cinacalcet slowed the progression of VC over VDRA therapy 
alone in hemodialysis patients [118]. However, a more recent EVOLVE study reported that 
cinacalcet failed to significantly reduce the risk of death or major cardiovascular events in 
patients with moderate-to-severe sHPT who were undergoing dialysis [119]. For 
progressive, biochemically-severe, and often symptomatic sHPT, surgical removal of a 
part of the parathyroid gland, known as parathyroidectomy, may be the treatment of choice. 
Subtotal parathyroidectomy has been shown to arrest the progression of CAC in dialysis 
patients [120]. In chronic hemodialysis patients who underwent total parathyroidectomy, 
retrospective evaluation of prognosis revealed that parathyroidectomy, atrial fibrillation 
(AF), and serum albumin were significant factors for total and especially cardiovascular 
mortality. Total parathyroidectomy was associated with better survival, probably due to 
decreased cardiovascular mortality [121].   
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Table 2-3: Secondary prevention strategies against VC. 
 
Treatment 
 
Mechanism of 
Action/Outcome 
References 
 
Secondary Prevention 
 
 
Hyperphosphatemia 
 
 
Dietary Phosphate Control 
 
Phosphate Binders 
 
 
Reduction of circulatory 
phosphate imbalance and 
reduced hyperphosphatemia 
 
 
 
 
 
Isakova, T., et al. 2011 [109] 
Hutchison, A.J., et al. 2011 
[110] 
Chertow, G.M., et al. 2002 
[111] 
Block, G.A., et al. 2005 [112] 
Russo, D., et al. 2007 [113] 
 
 
Secondary 
hyperparathyroidism 
 
 
 
 
Vitamin D Receptor 
Activators (VDRAs) 
 
 
 
Calcimimetics 
 
 
 
Parathyroidectomy 
 
 
Management of sHPT by 
minimizing 
hyperphosphatemia and 
hypocalcemia without 
causing hypercalcemia and 
overly suppressing PTH 
 
 
 
 
 
 
 
 
Teng, M., et al. 2003 [114] 
Tentori, F., et al. 2006 [115] 
Ogawa, T. et al. 2010 [116] 
Sprague, S.M., et al. 2003 
[117] 
 
Raggi, P., et al. 2011 [118] 
Investigators, E.T., et al. 2012 
[119] 
 
 
Bleyer, A.J., et al. 2005 [120] 
Iwamoto, N., et al. 2012 
[121] 
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In addition to these preventative treatment strategies, there have been several 
potential therapies that tried to directly target the calcification process. Pyrophosphate 
(PPi) is a powerful inhibitor of calcium crystallization that circulates at sufficient 
concentrations so as to prevent hydroxyapatite formation, thus serving as an endogenous 
inhibitor of calcification. PPi may be deficient in advanced renal failure and plasma levels 
of PPi may be reduced in dialysis patients. In general, an inverse association of PPi 
concentrations is seen with VC in CKD and ESRD patients [87]. Humans lacking 
ectonucleotide pyrophosphorylase (Enpp1), the enzyme that synthesizes extracellular PPi, 
are also known to develop several MAC at an early age. However, rapid hydrolysis of PPi 
in vivo limits this therapy and in turn prompted the development and use of 
nonhydrolyzable analogs, known as bisphosphonates.  
Studies, although small, with etidronate show a beneficial effect in CKD and ESRD 
patients. In a study with a mean patient age of 63.2±8.2 and mean duration of dialysis of 
7.4±5.5, 35 patients were administered etidronate for 14 days over three cycles. CAC 
progression in these patients was significantly less pronounced during treatment than 
compared to the period before treatment was initiated [122]. In another study with 
etidronate, patients with ESRD and undergoing dialysis three times per week were given 
etidronate orally for 23 months. Aortic calcification area (ACA) in these patients did not 
change over 23 months, but the control group had significantly elevated ACA scores [123]. 
Calcification scores of the coronary arteries, thoracic, and abdominal aorta collected by a 
multi-detector-row CT scanner showed that etidronic acid markedly reduced aortic 
calcification in patients with ESRD undergoing chronic hemodialysis [124]. There is still 
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a debate over efficiency of bisphosphonate therapy, and results differ by the agent in 
question; different studies suggest a beneficial role of etidronate, pamidronate to a little 
extent but not alendronate or ibadronate [125]. Owing to their potential effects on bone 
formation and accumulation in renal failure because of their clearance by kidneys, 
bisphosphonates are not recommended as a therapy for treatment of uremic vascular 
calcification.  
Table 2-4: Treatments directed against calcification mechanisms 
 
Treatment 
 
Mechanism of 
Action/Outcome 
References 
 
Calcification Mechanisms 
 
 
Pyrophosphates 
 
Bisphosphonates 
 
Reduce release of Ca2+ and 
prevents hydroxyapatite 
nucleation and growth 
 
 
O'Neill, W.C., et al. 2010 
[87] 
Nitta, K., et al. 2004 [122] 
Hashiba, H., et al. 2006 [123] 
Ariyoshi, T., et al. 2006 [124] 
Toussaint, N.D., et al. 2010 
[125] 
 
 
Thiosulfate 
 
 
Binds with vascular calcium 
salts to form a highly soluble 
calcium thiosulfate salt 
 
 
Araya, C.E., et al. 2006 [126] 
Mataic, D., et al [127] 
Adirekkiat, S., et al. 2010 
[128] 
Mathews, S.J., et al. 2011 
[129] 
 
 
Sodium thiosulfate (STS) is a small molecule acting as a vasodilator, antioxidant, 
and a calcium chelator in vivo. The use of thiosulfate to treat VC was devised due to reports 
that it prevents nephrolithiasis in humans, reduced tumoral calcifications in renal failure 
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and significantly because it was successful in treatment of Calcific uremic arteriolopathy 
(CUA) [126, 127]. In hemodialysis and peritoneal dialysis patients with CUA, parenteral 
infusion of STS was able to reduce skin necrosis and calcium deposits within three months 
of administration. In two preliminary studies with hemodialysis patients, STS was able to 
delay the progression of CAC after 4-5 months of intravenous administration but with a 
flipside of decline in bone mineral density of the hip in one study [128, 129]. Additional 
clinical trials are underway, and at this time, STS is not recommended for use elsewhere.  
Osteoclasts are the major mineral-resorbing cells in the body, and a landmark study 
from our laboratory found that when osteoclasts were co-implanted with elastin in rats 
subdermally, calcification was limited [130]. However, successful delivery and activation 
of osteoclasts to the site of calcification remains a challenge.  
 Animal models of Vascular Calcification 
Numerous animal models have been developed to study the cellular and molecular 
mechanisms underlying VC, and to investigate various treatment strategies against it. A 
variety of protocols in different animal species that produced calcifications at different 
locations on the aorta have been documented in literature. Some well-known models 
include Calcium chloride (CaCl2) injury of abdominal aorta, local intraluminal perfusion 
of pancreatic elastase, systemic delivery of warfarin and vitamin K, supraphysiologic 
dosages of vitamin D, nicotine used in combination with vitamin D, delivery indoxyl 
sulfate, etc.  
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The CaCl2 injury model has been used in rats, mice, and rabbits [131, 132]. Local 
chemical damage to the abdominal aorta (or any other parts of the aortic tree such as carotid 
or thoracic) by direct periadventitial application of CaCl2 causes localized medial 
calcification. There is minimal injury to the arterial wall, but the acute and excessive 
calcification is accompanied by elastin fiber breakdown and severe inflammation [133]. 
Warfarin inhibits γ-carboxylation of matrix Gla protein (MGP) and induces calcification 
of the arteries similar to what is seen in an MGP-deficient mouse. Vitamin K is also used 
in this model to restore normal coagulation as Warfarin is an anticoagulant, commonly 
prescribed to dialysis patients [134, 135].  
Calcitriol and other such vitamin D analogs are used to treat diseases in which VC  
is common, such as osteoporosis and hyperparathyroidism. But toxic doses, either daily 
intraperitoneal injections (1µg/kg) or supraphysiologic doses in diet (7.5 mg/kg), of 
Vitamin D and its analogs, causes calcification [136-138]. This toxic effect of vitamin D 
is both indirect (by causing an increase of circulating levels of Ca and P) and direct through 
VSMCs. Calcitriol has been known to stimulate calcium flux into VSMCs and thus 
modulates increased expression of several proteins associated with calcification.  
As discussed earlier, various other stimulants have also been administered in 
rodents to induce VC. Nicotine (5 ml/kg) amplifies the pro-calcific effects of vitamin D 
(25 mg/kg). Vitamin D and nicotine (VDN) induces a calcium overload in the arteries, 
resulting in medial and other widespread calcification [139]. The nicotine plus vitamin D 
model causes calcification similar to that in a senescent man and is naturally accompanied 
by systolic hypertension and LVH. Indoxyl sulfate (IS) is a uremic toxin that accelerates 
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the progression of CKD. In addition, IS promotes aortic wall thickening and aortic 
calcification along with colocalization of osteoblast-specific proteins. Thus, it is not only 
a nephrotoxic but also acts as a vascular toxin [140].  
Intraluminal infusion of elastase degrades elastin in the arteries, which in turn 
localizes calcification in the abdominal aorta. This model was tested in swines and rabbits 
[141]. In the elastase-treated arterial segments of swines, elastic fiber damage, reduction 
of smooth muscle cells in certain areas and a significant number of necrotic lesions and 
calcium deposits were observed within three weeks. New Zealand rabbit elastase-induced 
aneurysm of the common carotid artery and subsequent calcification is one of the most 
commonly used models to test the safety and efficacy of endovascular devices [142].  
Gene deletion in mice is an extremely useful technique to unearth the precise role 
of a particular protein in the development of VC. Several inhibitors, either local or 
systemic, such as MGP, fetuin-A, PPi are often dysregulated during the pathophysiological 
process of calcification [85, 87, 89]. Mice which are deficient in phosphaturic hormone 
fibroblast growth factor (FGF) 23 and its necessary cofactor Klotho exhibit extensive 
vascular and other soft tissue calcifications [85, 143]. Mice that lack MGP develop to term, 
but die within a couple of months as a result of arterial calcification leading to blood vessel 
rupture. MGP-deficient mice, besides, exhibit inappropriate calcification of various 
cartilages, including that of the growth plate, eventually leading to short stature, 
osteopenia, and fractures [84]. Osteoprotegerin (OPG) deficient mice also exhibit medial 
calcification of the aorta and renal arteries, suggesting that regulation of OPG, its signaling 
pathway, or its ligands play a role in the association between osteoporosis and VC [144]. 
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Schafer et al. identified the serum protein α2-Heremans-Schmid glycoprotein (Ahsg, 
commonly known as fetuin-A) as an important inhibitor of ectopic calcification acting on 
a systemic level. Ahsg-deficient mice are normal phenotypically, but develop several 
calcifications of various organs on a mineral and vitamin D-rich diet, and on normal diet 
when the Ahsg deficiency is on a DBA/2 background [145].  
 Rodents have a generally high resistance to the development atherosclerotic 
calcification. The lipid profile of rodents differs significantly from humans in that rodents 
carry most of their plasma cholesterol in the form of high-density lipoprotein (HDL), 
known to be a protector against atherosclerosis. Humans, on the other hand, have 75% of 
their cholesterol on low-density lipoprotein (LDL). However, mice of C57/BL6 genetic 
background are an exception.  Mice models based on interventions in lipoprotein 
metabolism through genetic and dietary manipulations are most commonly used to study 
atherosclerotic calcification.  ApoE, a glycoprotein which is a constituent of all lipoproteins 
except LDL, serves as a ligand for receptors involved in the clearance of very low-density 
lipoproteins (VLDL) from circulation. Deletion of this particular ApoE gene results in a 
definite increase in plasma levels of VLDL, increase in LDL to a lesser extent and a 45% 
reduction in normal HDL levels leading to development of atherosclerotic lesions, mainly 
in the aortic root and ascending aortas. A high fat, high cholesterol diet leads to the 
development of more widely distributed and complex atherosclerotic plaques in these 
ApoE knockout mice [146-148]. The LDL receptor (LDLR) knockout mice represent 
another frequently used genetic model for atherosclerosis. LDLR knockout shows a modest 
increase in lipid levels, doubling of plasma cholesterol mainly due to elevated LDL levels 
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and little to no atherosclerosis when fed a regular chow diet. When fed with a 1.25% 
cholesterol-rich diet, LDLR knockout mice display an eight-fold increase in plasma 
cholesterol levels and show rapidly developing atherosclerotic lesions throughout the 
length of the aorta. Administration of high-cholesterol, high-fat diet to these mice causes a 
2-fold increase in aortic calcification and decreased rate of bone formation [149, 150].  
 
Table 2-5: Animal models for in vivo calcification studies. 
 
 
Type of Animal Model 
 
 
Method of induction 
of disease 
 
 
Animal Species 
 
References 
 
Calcium Chloride 
model 
 
 
Periadventitial 
application of CaCl2 
 
Rats, Mice, Rabbits 
 
[131-133] 
 
Warfarin/Vitamin K 
 
Warfarin in drinking 
water/Vitamin K 
Subcutaneous injections 
 
 
Rats 
 
[134, 135] 
 
Vitamin D 
 
Daily intraperitoneal 
injections or supra-
physiological vitamin D 
doses in diet 
 
 
Rats 
 
[136-138] 
 
Genetically induced 
models 
 
Knockout of regulators 
of calcification (FGF23, 
Klotho, MGP, OPG or 
Fetuin-A) 
 
 
Mice 
 
[84, 89, 143, 144, 151, 
152] 
 
Nicotine Model; usually 
used in combination 
with Vitamin D 
 
Oral administration of 
Nicotine amplifies 
the calcifying effects 
of Vitamin D 
 
 
Rat 
 
[139] 
 
Indoxyl Sulphate Model 
 
 
Administration of 
Indoxyl Sulphate in 
water 
 
 
Rats 
 
[140] 
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Elastase Model 
 
Intraluminal delivery of 
elastase causes 
breakdown of elastin 
fiber 
 
 
Rats, Mice, Swine, 
Rabbits 
 
[141, 142] 
 
 
5/6th Nephrectomy 
Model of CKD 
 
 
Reduction in renal 
mass is usually installed 
by a two-stage surgical 
procedure: 
partial nephrectomy of 
one kidney and total 
nephrectomy of 
the contralateral kidney 
 
 
 
Rats, Mice 
 
 
[153-155] 
 
Dietary adenine induced 
CKD model 
 
High adenine feeding 
leads to structural and 
functional damage to 
kidneys causing 
increased Serum Ca 
levels and calcification 
 
 
Rats, Mice 
 
[156-159] 
 
Genetic models of 
atherosclerotic 
calcification 
 
 
ApoE-/- knockout mice 
Ldlr-/- knockout mice 
 
Mice 
 
[146-150] 
 
 Animal Models of CKD with Vascular Calcification 
Animal models of CKD generate a range of severity in calcification phenotype 
attributable to a lack of consistency in the genetic backgrounds used, degree of kidney 
damage induced, time course of study, and dietary regimen selected.  
 The 5/6th nephrectomy model or remnant kidney rat model reproduces experimental 
CRF by mimicking the progressive loss of nephrons that occurs in human CRF. It was first 
developed by Chauntin and Ferris in 1932 and has been used ever since [160]. In this 
model, reduction in renal mass is usually achieved by a two-stage surgical procedure: 
43 
 
partial nephrectomy of one kidney and then a total nephrectomy of the contralateral kidney. 
Different methods are employed to perform the nephrectomy; resection or ligation of the 
upper and lower poles of the kidney [161], cauterization or electrocoagulation of the renal 
cortex and arterial ligation [162]. Out of the three, arterial ligation of 2/3rd of extrarenal 
branches of the renal artery of the kidney, performed on one combined with resection of 
the other kidney is the most commonly used rat model of 5/6th nephrectomy model. 
However, the major limitations of 5/6th model for study of vascular calcification include 
requirement of the two-step surgical procedure combined with the need to use either an 
accelerating agent such as Vitamin D, excessive dietary phosphate levels or surgical 
removal and replacement of parathyroid glands [163]. 
 Rats with autosomal dominant polycystic kidney disease result in spontaneous 
development of CKD over time. Heterozygous Han: SPRD rats (Cy/+) develop azotemia 
at 10 weeks and progress to uremia by about 40 weeks of age, accompanied by anemia, 
hypertension, hyperlipidemia, and sHPT [164, 165]. In this model, Moe et al. reported that 
all three components of CKD viz., abnormal serum biochemistries, abnormal bone 
remodeling and calcification of the tunica media are induced when fed a normal 0.7% P 
diet. 60% of the animals developed mild to severe calcifications of the aorta after 38 weeks 
of age [166]. The main disadvantage of this model, however, particularly for its usage in 
interventional studies, is the very slow progression of CRF and as such the late onset of the 
first calcified spots in the arteries, combined with limited reproducibility.  
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 Adenine-Induced Chronic Kidney Disease Model 
In normal conditions, adenine is salvaged by the enzyme adenine 
phosphoribosyltransferase (APRT) enzyme and is generally present in very low levels in 
circulation and urine. APRT is expressed ubiquitously in all mammalian cells and plays an 
important role in the purine nucleotide salvage pathway helping in recovery of bases and 
nucleosides following degradation of RNA and DNA. It represents the rate-limiting step in 
the conversion of adenine and 5-phosphoribosyl-1-pyrophosphate (PRPP) to adenosine 
monophosphate (AMP). ARTP catalyzes a phosphoribosyl transfer from PRPP to adenine, 
forming AMP and releasing pyrophosphate.  
When adenine administration exceeds a certain level, APRT activity is insufficient 
and saturated. Adenine is then oxidized by xanthine dehydrogenase to 2,8 
dihydroxyadenine (DHA) via an 8-hydroxyadenine intermediate product. Although DHA 
is protein-bound in plasma, it has a general poor solubility in urine and gradually 
precipitates in the kidney tubules, leading to the formation of kidney stones, i.e., 
nephrolithiasis [167]. If left untreated, it results in renal failure with permanent kidney 
damage. The autosomal recessive metabolic disorder, APRT deficiency represents the 
human counterpart of this phenomenon [168]. 
The adenine model has recently gained a lot of attention due to the relative ease in 
design and several encouraging outcomes. Long term high adenine feeding in rats results 
in certain metabolic abnormalities resembling CRF in humans. Among the disturbances 
observed are azotemia, accumulation of uremic toxins, imbalance of amino acids and 
electrolytes, and other hormonal imbalances [169]. Adenine forms crystals in the renal 
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tubules causing subsequent tubular injury, seen as lesions in mainly proximal tubules, some 
distal tubules and glomeruli, inflammation, and noticeable fibrosis. These marked kidney 
damages go along with characteristic biochemical changes like significantly elevated 
serum creatinine, blood urea nitrogen, and phosphorus. Renal pathology of the adenine 
model resembles the clinical situation quite well with the presentation of 
hyperphosphatemia, hypocalcemia, severe secondary hyperparathyroidism with high 
parathyroid hormone levels, hypovitaminosis of D, and renal osteodystrophy. Okada et al. 
optimized the adenine-induced CKD model in rats that closely resembles the clinical 
condition in humans [170]. It has since become a useful model to study complications of 
CKD in patients.  
Several research groups made use of the adenine model to evaluate therapeutic 
agents for prevention of medial calcification [156, 159, 171-175]. The key advantage of 
the adenine model is that it does not mandate surgery to generate required levels of CKD. 
However, its major drawback is that up to 50% of the animals do not show medial aortic 
calcification despite the manifestation of a stable, comparable moderate-severe CKD. 
Another significant disadvantage is the severe weight loss that occurs with feeding of high 
adenine and ensuing mortality [176]. Price et al. introduced a variant on this model by 
lowering the protein content of the adenine-rich diet to 2.5% along with high amounts of 
Ca (1.06 %) and P (0.92%). This combination resulted in the development of uniformly 
severe medial calcification in the aortas of all rats 4 weeks after the induction of CKD. 
Lowering the protein content of the diet dramatically increases the frequency and extent of 
medial artery calcification [157].  
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Table 2-6: Studies with adenine-model of CKD in rodents 
Reference Animals Diet 
 
Duration of adenine 
feeding 
 
Price et al. [157] 13 wk old SD rats 
 
0.75% Ad 
0.92% P 
1.06% Ca 
2.5%/25% Protein 
 
4 wk 
 
Katsumata et al. 
[156] 
 
 
 
12 wk old Wistar 
Rats 
 
0.75% Ade 
0.92% P 
1.06% Ca 
4 wk 
Lomashvilli et al. 
[177] 300g SD rats 
 
0.75%/0.5% Ad 
0.92% p 
10.6% Ca 
 
4 wk 
 
Yamada et al. [178] 
 
10 wk old SD rats 
 
0.75% Ad 
1.2% P 
1.0% Ca 
 
4 wk/6 wk 
 
Neven et al. [159] 
 
 
10 wk old Wistar rats 
 
 
0.75% Ad 
0.92% P 
1.1% Ca 
 
4 wk 
 
Henley et al. [171] 
 
 
350-390g SD rats 
 
 
0.75% Ad 
0.9% P 
1.1% Ca 
 
 
4 wk 
 
 
Pasch et al. [179] 
 
 
6 wk old Wistar rats 
 
 
0.75% Ad 
0.8% P 
1.05% Ca 
 
4 wk 
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  Chelation Therapy   
 Chelation has its origin in the Greek word ‘chela’ meaning claw of a lobster, thus 
describing the concept of clinging or holding with a strong grip. The term chelate was first 
applied by Sir Gilbert T. Morgan and H. D. K. Drew in 1920. They suggested the term for 
the caliper-like groups which function as two associating units and fasten to a central atom 
so as to produce heterocyclic rings [180].  
 
Figure 2-15: Chelating agent-metal ion complex. (A) Depiction of chelating agent binding 
to metal ion in a crab-like grip. (B) EDTA-Metal ligand complex [181].  
 
 Chelation therapy mainly involves the usage of Ethylene diamine tetraacetic acid 
(EDTA), a chemical that binds to, or chelates ionic calcium, trace elements, and other 
divalent cations. Chelation therapy can be traced back to the early 1930s when Ferdinand 
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Munz, a German chemist first synthesized EDTA while he was looking for a replacement 
for citric acid as a water softener [182].  Usage of chelation for therapy began during World 
War II when some chemists at the University of Oxford were researching for an antidote 
to lewisite, an arsenic-based chemical weapon [183]. It was learned that EDTA was 
particularly effective in treating lead poisoning. Following this, chelation therapy was used 
to treat workers who had painted US naval vessels with lead-based paints and were 
suffering from lead poisoning. It remains in use for some very specific medical purposes, 
although it needs to be administered under extremely careful supervision, owing to its 
many inherent risks. In fact, it is one of the preferred medical treatments against many 
forms of metal poisoning (e.g., lead, arsenic, mercury, iron, copper, and nickel) [184]. 
Heavy metal poisoning can be caused by drinking polluted water, breathing heavily 
polluted air, and due to several conditions that lead to a buildup of toxic metals in the body, 
such as Wilson’s disease, hemochromatosis, thalassemia, sickle-cell disease, etc.  
 Types of chelating agents 
There are multitudes of chelating agents with different affinities for different 
metals, physical characteristics, and their mechanism of action in the body. These agents 
may be administered intravenously, intramuscularly, or orally depending on the agent and 
need. Some chelating agents that have been used as chelation therapeutics for various 
medical purposes against metal intoxication are listed in Table 2-7. 
Apart from its usage in alternative medicine to treat metal toxicity as discussed, 
chelation therapy has also been advocated for conditions like atherosclerosis, diabetes, 
autism, Alzheimer’s, and Parkinson’s disease. However, all these claims are largely 
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unproven, and chelation therapy is only approved by the U.S. Food and Drug 
Administration (FDA) to treat metal poisoning [185, 186]. 
Table 2-7: Chelation therapy for metal intoxication 
 
Type of chelating agent 
 
 
Target metal and 
medical application 
 
Route of 
Administration 
 
References 
 
EDTA 
 
 
Lead, Calcium 
 
Intravenous 
 
[187-190] 
 
Calcium disodium 
EDTA 
 
 
 Mercury, Lead 
 
Intravenous 
 
[191-193] 
 
STS (Sodium 
thiosulfate) 
 
 
Antioxidant 
Cyanide Poisoning 
Skin Diseases like 
Acne  
 
 
Intravenous 
 
 
[194] 
[195] 
 
DTPA (Diethylene 
triamine pentaacetic 
acid) 
 
 
MRI contrast agent, 
Radioactive poisoning 
with Plutonium, 
Americum, etc. 
 
 
Intravenous 
 
[196] 
[197] 
 
Dimercaprol 
also known as BAL 
(British anti-Lewisite) 
 
 
Arsenic, Mercury, Lead 
poisoning 
Copper poisoning 
(Wilson’s disease) 
Lewisite poisoning 
 
 
 
 
Intramuscular injection 
 
[198] 
 
[199] 
 
[200, 201] 
 
 
DMSA 
(Dimercaptosuccinic 
acid) 
 
 
 
Mercury, Arsenic and 
Lead poisoning 
 
 
 
Oral 
 
 
 
[202-204] 
 
DMPS (Dimercapto-
propane sulfonate) 
 
Acute Arsenic 
poisoning 
Polonium poisoning 
Mercury poisoning 
 
 
Oral 
 
Intravenous 
 
 
 
[205] 
 
[206] 
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D-Penicillamine 
 
Lead, Arsenic, 
Mercury poisoning 
Copper poisoning in 
Wilson’s disease 
 
 
Oral or 
Intravenous 
injections 
 
[207] 
 
[208] 
 
 
Deferoxamine and 
Deferasirox 
 
 
Iron poisoning 
(Thalassaemia)  
Aluminum poisoning 
(Chronic renal 
dialysis) 
 
 
 
Intravenous injection 
or 
infusion 
 
 
[209, 210] 
 
 
 EDTA Chelation Therapy 
 EDTA binds to and forms strong complexes with iron, mercury, lead, calcium, trace 
elements, and other divalent cations. Table 2-8 shows EDTA and its binding affinity to 
various metal ions. 
Table 2-8: EDTA and its Log K binding constants to various metal ions. 
Metal Fe3+ Hg2+ Cu2+ Pb2+ Ni2+ Zn2+ Cd2+ Co2+ Al2+ Fe2+ Mn2+ Ca2+ Mg2+ 
Log K 25.1 21.8 18.8 18.5 18.0 16.5 16.5 16.3 16.1 14.3 13.7 10.7 8.7 
 
 Higher binding constants indicate the binding potential of the chelating agent to the 
respective metal ion. Owing to its large binding affinity to Pb2+, EDTA has been used for 
decades to treat lead poisoning, as we discussed before. EDTA also has an appreciable 
binding affinity to Ca2+, therefore has been used to treat hypercalcemia, removal of calcium 
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from fixed tissues and has long been advocated as an alternative treatment approach for 
CVDs [9, 187, 211].  
There have been many case studies and clinical trials to claim that EDTA chelation 
therapy is effective against atherosclerosis, coronary heart disease, and peripheral vascular 
disease. It began with Norman Clarke, Sr. and his coworkers in the 1950s who observed 
that some of the workers at a battery factory had improved angina pectoris following 
chelation therapy. He subsequently administered chelation therapy to patients with angina 
and other occlusive vascular problems, hypothesizing that “EDTA could dissolve disease-
causing plaques in the coronary systems of humans” [188]. In a subsequent longer study, 
Clarke et al. showed that 87% of patients out of 283 showed improvement in their 
symptoms [212]. Quite a few investigators made similar observations about the role of 
EDTA in the treatment of cardiovascular disease [213-217]. In a retrospective study of 
2,870 patients treated with NaMgEDTA, Olszewer and Carter noted that EDTA chelation 
therapy benefited patients with cardiac disease, peripheral vascular disease, and 
cerebrovascular disease. The conclusions were unjust due to a lack of comparison with 
people who did not receive the treatment. The same researchers carried out a double-blind 
study in which patient progress was evaluated by measuring blood pressure changes, 
performance in stress tests before, during, and after EDTA treatment. It was claimed that 
the treatment showed substantial improvements in walking and master exercise tests [218]. 
McDonagh et al. reported a case study with 30 patients diagnosed with atherosclerotic 
vascular disease and showed that EDTA chelation therapy decreased intra-arterial 
obstruction and reduced stenosis [219]. In a retrospective case study in 470 patients acting 
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as their own control, Claus Hancke and his group observed that 80-91% of them showed 
improvement. Amongst 92 patients referred for surgical intervention, only 10 ultimately 
required surgery during, or after chelation therapy [220].  
Results from other randomized, placebo-controlled studies, however, do not 
indicate any benefit from EDTA on CVD. The first of these studies was conducted by 
Diehm et al. with 45 patients who had a high-grade arterial obstruction and intermittent 
claudication, by measuring their ability to perform pain-free walking exercises along with 
many other parameters. Measurements made during the 4-week treatment period, and for 
3 months after treatment, showed that both EDTA and control Bencyclan groups showed 
comparable improvements [221]. Guldager and coworkers published a double-blind, 
placebo-controlled trial with 153 patients who received either EDTA (3g of Na2EDTA) 
placebo. At the end of the 5-9 week treatment phase, there were no significant inter-group 
differences in any of the outcome parameters, and the situation remained unchanged even 
after 6 months of follow-up [222]. Another placebo-controlled, double-blind study was 
published by van Rij et al. randomizing 32 patients with intermittent claudication into 
treatment and control groups. No clinically significant differences in main outcome 
measures (subjective and measured walking distances, ankle/brachial pulse indices) 
between chelation therapy and placebo groups were detected up to 3 months following 
treatment [223]. In 2002, Knudtson et al. enrolled 84 patients over 21 years of age with 
coronary artery disease proven by angiography, or documented myocardial infarction and 
stable angina. Based on exercise time to ischemia, exercise capacity, and quality of life 
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measurements, they found no evidence to support a beneficial effect of chelation therapy 
[224].  
The use of chelation therapy to treat heart diseases and other conditions grew in the 
United States by approximately 68% to about 111,000 people. The Trial to Assess 
Chelation Therapy (TACT) was the first large-scale, NIH funded, multi-centered study 
commissioned from 2008 to 2013 to determine the safety and efficacy of EDTA Chelation 
Therapy (disodium EDTA) for individuals with a history of heart attacks. It was a study 
with a large enough design to detect if there are any moderate benefits towards risks 
associated with the therapy. Overall, patients who received chelation therapy had a modest 
18% reduced risk of subsequent cardiac events such as heart attack, stroke, and 
hospitalization for angina. These results, by themselves, are not sufficient to recommend 
routine use of chelation therapy for post-heart attack situations. Interestingly, among 
patients with diabetes (these patients made up 37% of the entire study population), 
researchers found that those receiving chelation had a markedly lower risk of 
cardiovascular events (25% in diabetic patients vs. 38% in placebo) and death due to any 
cause was 43% lower [190, 225]. A new follow-up study, Trial To Assess Chelation 
Therapy 2 (TACT2) commenced in December 2016 and is underway until 2021. NIH is 
sponsoring TACT2 to repeat the TACT1, but only in patients with diabetes and a prior 
heart attack to confirm the apparent benefit of EDTA chelation therapy in this group of 
patients [226]. Despite countless claims and opinions against the use of EDTA chelation 
therapy in the treatment of CVDs, there is enormous potential, as long as the possible side-
effects can be circumvented. 
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 Nanoparticles as drug delivery systems  
 In the treatment of vascular diseases, direct administration of drugs has shown 
limited success largely because of rapid drug clearance, short half-life, and severe systemic 
side effects. In addition, disturbed flow condition in the arteries is an important factor to 
consider while developing an effective therapy for vascular disease [227]. Nanoparticles 
(NPs) have certain unique features that enable them to be used in drug delivery to specific 
tissues or organs to maximize the beneficial effects of the drug by improving local 
availability and lower off-target complications. The tunability of their shape, size, and 
surface chemistry makes NPs suitable to be programmed for site-specific delivery. NPs 
achieve their central goal of site-specificity by exploring considerations of normal versus 
diseased tissues to optimize their residence time [228-230].  
 Several types of nanocarriers have been developed for use in medicine, each with 
their own advantages and disadvantages. These include micelles, reverse micelles, 
dendrimers, liposomal nanocarriers, polymeric nanoparticles, nanogels, and nanocoatings. 
Among these, only polymeric and liposomal nanoparticles have been extensively studied 
for drug delivery in vasculature because of their high biocompatibility and 
biodegradability. Further, they present a variety of possibilities for surface-modification 
and high drug payload [231, 232]. Polymeric nanocarriers have proven to be more effective 
in delivering drugs to vascular wall than their liposomal counterparts, owing to liposome’s 
inherent issues such as thinner membranes affecting their durability, and destabilization 
due to addition of polyethylene glycol (PEG). As NPs being targeted to vascular disease 
have to be administered intravenously into circulation, an immune response, known as 
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opsonization, to the blood proteins that are absorbed onto the particle surface will occur 
[233]. This will result in the particles being quickly eliminated from circulation by the 
Mononuclear phagocyte system (MPS) [234], and the desired therapeutic effect is not 
achieved. Surface addition of PEG chains to polymeric NPs, a process termed PEGylation, 
increases their hydrophilicity, reduces immunogenicity, and increases their retention time 
by making them “stealthy”. [235].  
 Targeting of NPs can be achieved either by passive or active targeting mechanisms. 
Passive targeting is commonly used in oncology because the tumor results in enhanced 
permeability and retention (EPR) effect [236, 237]. NPs preferentially accumulate near 
tumor sites due to blood vessel leakage, or limited lymphatic drainage. Active targeting is 
a result of surface modifiers such as ligand/receptor, antigen/antibody, or any other form 
of molecular recognition, to ensure that the NPs are guided to the tissue of interest [238, 
239].  
 Albumin use for formulation of nanoparticles 
 Albumin is a versatile macromolecule for drug delivery because it is known to be 
non-toxic, non-immunogenic, biocompatible, and biodegradable. In recent times, albumin-
based nanoparticles have emerged as attractive drug carriers, since a significant amount of 
drug can be loaded into the particle matrix because of high binding sites present in the 
albumin molecule [240]. Albumin can be obtained from a variety of sources, including egg 
white (ovalbumin), bovine serum albumin (BSA), and human serum albumin (HSA). 
Albumin NPs are expected to be well tolerated, as evidenced by clinical studies with 
registered HSA-based particles such as Albunex™[241] and Abraxane™ [242].  
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 Albumin nanoparticles can be prepared using a variety of techniques [240]; 
desolvation, emulsification, thermal gelation, nanospray drying, and nab™. In the process 
of desolvation, albumin is phase-separated out from a solution by the addition of a 
desolvating agent due to its diminished solubility. Glutaraldehyde is then used as a 
crosslinker to harden the coacervates.  Other crosslinkers, such as polyethyleneimine (PEI), 
formaldehyde, and 1-ethyl-3-(3-dimethylaminopropyl) cardodiimide (EDC) have been 
suggested as alternatives to glutaraldehyde for reduced toxicity [243].   
 Targeted or Site-specific EDTA Chelation Therapy 
 The usage of systemic chelation therapy with EDTA, as discussed above, requires 
high dosages resulting in possible unwanted side effects such as hypocalcemia, renal 
toxicity, and bone loss [10, 244]. The major drawback to any systemic treatment is that 
very small amounts of the drug (in this case, chelating agent) actually reach the site of 
mineralization. Another notable hurdle for systemic attempts to reverse VC is that calcium 
is typically present in blood, bones, and teeth, and is required for normal functions in these 
tissues.  Therefore, removal of calcium from arteries through systemic approaches can have 
major and potentially disastrous complications. Targeted and site-specific delivery of 
EDTA could lower the dosage required and present attractive advantages such as improved 
bioavailability and control over release of the chelating agent. 
 In our laboratory, we have developed a nanoparticle approach with albumin-based 
NPs that only targets degraded elastin fiber, which is a salient feature of calcified arteries. 
As noted previously, elastic fibers are made up of a core of crosslinked amorphous elastin, 
and several microfibrillar glycoproteins (such as fibrillins and fibulins) on the periphery of 
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the amorphous core. Consequent to elastic fiber degradation and calcification, the 
surrounding microfibrillar proteins are lost, and the amorphous core is exposed. This 
exposed core serves as a potential target for nanoparticles conjugated on their surface with 
an elastin-specific antibody [245].   
 
Figure 2-16: Elastic fiber degradation leads to exposed amorphous core 
  
 Several key studies performed and published from our laboratory have shown the 
success of such site-specific targeted therapies with albumin NPs aimed to target damaged 
elastic fiber in the treatment of elastin-specific diseases including abdominal aortic 
aneurysm [246-248], emphysema and chronic obstructive pulmonary disease (COPD) 
[249]. 
 
 
 
Elastin lamina degradation in diseased 
artery
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3 PROJECT RATIONALE AND SPECIFIC AIMS 
 
 Therapeutic strategies and interventions that may stabilize and potentially reverse 
vascular calcification (VC) are of immense value to patients with chronic kidney disease 
(CKD). As discussed at length in the previous chapter, most of the treatment methods in 
use have been generally limited to optimizing and managing the dysregulated mineral 
metabolism and bone turnover diseases, both of which are characteristic to CKD itself. It 
is pertinent to note here that there is no consensus yet about screening for, and interventions 
to retard the progression of VC. Even with the most dramatic interventions in use, namely 
intense dialysis and renal replacement therapy, VC that has already manifested in patients 
cannot be regressed.  
 Current clinical practice entirely focuses on prevention and retardation of 
progression. Unfortunately, most patients remain underdiagnosed, and those diagnosed 
already have heavily calcified vessels thereby remaining undertreated since preventative 
strategies no longer work at this stage of diagnosis. Therefore, it becomes essential that the 
process of treatment of VC involves direct interference with mineralization in the arteries 
and resorption of calcified lesions. Promoting this process of reversal, while 
simultaneously avoiding demineralization from tissues that normally contain calcium (i.e., 
bones and teeth) remains the most critical challenge with respect to developing a successful 
treatment regimen for VC in CKD. Unfortunately, there is no FDA-approved treatment 
available at this time to reverse calcification in millions of patients with CKD. Finding a 
treatment approach that attacks and dissolves mineralization in the calcified arteries of 
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these patients, while eluding systemic loss of calcium, thus improving arterial elasticity 
remains a pressing health care necessity.  
 Chelating agents are chemical compounds known to react with metal ions to form 
stable and water-soluble complexes. They have long been of great importance in treating 
intoxications and metal overload in the body. Some critical qualities of a chelating agent 
to exert its clinical effect are high affinity towards the toxic metal, forming the metal-
chelator complex with rapid elimination, and low toxicity. EDTA is a well-known chelator 
and has a high affinity towards a variety of metal ions, including Ca2+. Ethylene glycol 
tetraacetic acid (EGTA) is a polycaroboxylic acid similar to EDTA and can also act as a 
chelating agent. It is reported to have a better affinity towards Ca2+ than EDTA. A 
polycarboxylic acid derivate of EGTA, known as (1,2-bis(o-aminophenoxy) ethane- N, N, 
N’, N’ tetraacetic acid (BAPTA), is also known for its calcium-specificity and ability to 
bind two Ca2+ ions in solution, Both EGTA and BAPTA have been used to chelate Ca2+ in 
buffers, especially in the presence of other metal ions like Mg2+. Because of their affinity 
for Ca2+, we theorize that these chelating agents can chelate and remove Ca from 
mineralized deposits. 
   Our innovative tactic is to target the amorphous elastin core that is exposed when 
elastin fibers degrade and calcify. NPs conjugated with an anti-elastin antibody will 
accumulate at the calcified sites, sparing healthy arteries and other tissues. This will allow 
us to deliver any agent to these degraded and calcified elastin fibers. The chelating agent 
released at these sites will dissolve and remove calcium from the mineralized deposits. 
Site-specific delivery of chelating agent helps us to avoid systemic side effects commonly 
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seen with intravenous chelation therapies currently in use. If successful, this approach will 
create a new paradigm in the quest to invent a novel therapy for permanent reversal of 
vascular calcification.  
Specific Aim 1: To compare and contrast the chelating agents EGTA and BAPTA with 
EDTA and deduce the chelating agent most effective in demineralizing calcium for 
use in targeted chelation therapy of VC. 
Rationale: EDTA is a popular chelating agent in the treatment of metal intoxication due to 
lead, and calcium owing to its well-published affinity towards many metal cations. EGTA 
is useful for making buffers to chelate Ca ions when they are less concentrated than others, 
as found in living cells and chelating certain heavy metal poisons. BAPTA-AM has been 
known to maintain intracellular Ca2+ homeostasis.   In this aim, we would like to compare 
the chelating ability of these three chelating agents in vitro to select the best among the 
three for our targeted EDTA chelation therapy experiments.  
Specific Aim 2: To investigate whether EDTA, a chelating agent, loaded nanoparticles 
(NPs) can be targeted to the sites of elastin-specific medial arterial calcification 
(MAC) and whether the calcification can be reversed in a renal failure model in rats. 
Rationale: We have already shown elastin antibody-conjugated nanoparticle delivery 
system delivers EDTA to the sites of vascular calcification in a calcium chloride abdominal 
aorta injury, and calcification is eliminated from these sites. One significant limitation of 
this study was that the calcification that manifests in the CaCl2 model is restricted to the 
injury site in the abdominal aorta. Moreover, the calcification caused is because of an 
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inflammatory response to the periadventitial application of CaCl2 and may not be relevant 
clinically. Diabetic or renal failure patients would have calcification due to different 
pathomechanisms, and not due to chemically created injury. To address this limitation, we 
have chosen a renal failure model in rats caused by dietary administration of adenine. 
Specific Aim 3: To establish and validate adenine-induced CKD model of medial 
arterial calcification in mice by monitoring disease progression in vivo and exploring 
VSMC status for potential use in investigating targeted EDTA chelation therapy and 
effect of reversal of calcification on vascular homeostasis and function.   
Rationale: As cited earlier, we and several research groups have shown VSMCs 
undergoing differentiation and osteoblast-like transformation in VC. Recently, we have 
shown that osteogenic transdifferentiation of VSMCs occurs when cultured on surfaces of 
HA and calcified elastin. Interestingly, when cells were removed from the calcific 
environment and cultured normally, they revert to their VSMC phenotype. However, 
whether this is possible in vivo remains a challenge. Lineage tracing studies will be useful 
to investigate the fate of VSMCs in vivo after elimination of calcification by EDTA 
treatment. Since mice need to be used for lineage tracing studies, there is a need to establish 
a mouse model where CKD-related MAC is manifested and can be targeted. We would 
also like to develop imaging modules to track the progression of disease before and after 
treatment to assess improvement in vascular health following clearance of mineralized 
deposits and reverting of VSMCs to their contractile phenotype. 
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Specific Aim 4: To develop an ex vivo porcine carotid artery organ culture model of 
vascular calcification for evaluating whether treatment with EDTA loaded 
nanoparticles conjugated with an anti-elastin antibody eliminates calcification and 
reverts VSMCs to their normal phenotype  
Rationale: A large number of studies have been conducted using cell cultures from mice, 
bovine, and human to better understand the core mechanism of VC. High morphological 
and genetic variation at higher passage numbers limit the suitability of monolayer cell 
cultures to examine the influence of interaction between different cells and thus do not 
provide a full picture of VC and ensuing phenomena. Organ cultures are simple, relatively 
easy, and a better fit to inspect VC and nearly resemble an in vivo condition. An ex vivo 
organ culture model from a larger animal than rodents would be a logical step forward. We 
intend to use a porcine carotid artery organ culture model of Pi-induced calcification to 
scrutinize VC and VSMC cell fate after chelation therapy. 
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4 SPECIFIC AIM 1 
TO COMPARE EGTA AND BAPTA WITH EDTA AND DEDUCE THE 
CHELATING AGENT MOST EFFECTIVE IN DEMINERALIZING CALCIUM 
FOR USE IN TARGETED CHELATION THERAPY  
 
 Introduction 
 EDTA is a popular chelating agent for divalent ions, which is widely used in 
biochemistry, molecular biology, and cell biology. In addition to Ca, EDTA forms 
especially strong complexes with Mn, Cu, Fe, Pb, and Co. Ethylene glycol-bis (β-
aminoethyl ether)-N, N, N´, N´-tetraacetic acid or Ethylene glycol tetraacetic acid, or 
simply known as Egtazic acid is an aminopolycarboxylic acid and can act as a chelating 
agent, just like EDTA. In comparison to EDTA, it has a lower affinity for Mg2+, in turn 
making it more selective for Ca2+. EGTA is known for its high specificity for Ca2+, more 
so in the presence of Mg2+ [250]. It has been used to buffer solutions that resemble living 
cell environment, where Ca2+ ions are 1000-fold or so lesser concentrated than Mg2+ ions. 
Although EDTA is in more widespread use currently, EGTA is also used in some 
applications like treating animals with cerium poisoning, separation of thorium from 
monazite and as a component in elution buffers for protein purification. A synthetic 
derivative of EGTA, 1,2-bis(o-aminophenoxy)ethane-N,N,N′,N′-tetraacetic acid (BAPTA), 
is also known for its preference for Ca2+ ions in solution [251]. It is known to reduce 
elevation of cleaved Caspase-3, block cell death by inhibiting Reacting oxygen species 
(ROS) and eliminate intracellular changes of Ca2+ [252, 253]. 
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 Here, we try to assess the Ca chelating ability of the three chelating agents with a 
simple in vitro experiment using hydroxyapatite (HA) to select the better chelator for use 
in targeted EDTA chelation therapy.  
 Materials and Methods 
 Demineralization of HA in vitro by chelating agents  
 5 mg of hydroxyapatite powder was suspended in 30 mL solutions of three different 
chelating agents – EDTA, EGTA, and BAPTA. Two different concentrations (0.5 mg/mL, 
5mg/mL) of each chelating agent were used. DD water was used as control group. At 
regular intervals, 1mL of supernatant was withdrawn to quantify Ca that was released into 
the supernatant. Samples were analyzed using the Spectro Acros ICP Spectrometer 
(SPECTRO Analytical Instruments, Kleve, Germany) at Clemson University Agricultural 
Service Laboratory and Ca amounts were normalized to the initial amount of HA in the 
solution. 
 Measurement of MMP activity in tissue homogenates 
 MMP activity in homogenates of lung tissue samples from emphysematous mice 
was measured using internally quenched peptide substrates for MMPs 2&9 (Ex/Em = 
280/360 mm, MMP Substrate III, Anaspec, CA). One milligram of the substrate was 
dissolved in 50µl of DMSO, and the solution was diluted in 10 ml of development buffer 
(50 mM Tris Base, 5 mM CaCl2.2H20, 200 mM NaCl, 0.02% brij-35). 2 µl of the substrate 
stock solution and 2 µl of the homogenized tissues were mixed with 96 µl of the 
development buffer supplemented with any of the three chelating agents (EDTA, EGTA, 
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BAPTA) and incubated for one hour at 37°C. A fluorescent plate reader was used to read 
endpoint fluorescent intensity.  
 Results 
 Ca demineralized from HA by chelating agents  
 Three chelating agents (EDTA, EGTA, and BAPTA) at two different 
concentrations (0.5 mg/mL and 5 mg/mL) were tested to classify the best performing 
chelating agent with the highest propensity to release Ca. HA powder (5 mg in 30mL of 
chelating agent solutions was extracted at different time intervals and Ca measured through 
ICP analysis. EDTA was the stronger chelating agent amongst the three over a time period 
of 48 hours, removing Ca from HA at higher efficiency (~63 µg of Ca/mg of HA) than 
both EGTA and BAPTA, with 5 mg/mL EGTA (61.73 µg of Ca/mg of HA) reaching the 
level of demineralization of EDTA. Even at a higher concentration of 50 mg/mL, BAPTA 
was not as competent as EDTA in demineralizing Ca from HA powder in suspension with 
Ca released into the supernatants peaking at 51.4 µg of Ca/mg of HA for 5 mg/mL 
concentration. Negligible amounts of Ca were recorded with the control DD H20. The 
release kinetics of all the three chelating agents are shown in Figure 4-1. 
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Figure 4-1: Demineralization and Ca release kinetics from HA by chelating agents. EDTA 
releases Ca most efficiently compared to EGTA and BAPTA at both the concentrations 
used.  
 
 
 
 Measurement of MMP activity in tissue homogenates 
 To compare the MMP inhibitory effect of the three chelating agents on the tissue 
homogenates of lungs from emphysematous mice, MMP activity was measured using a 
specific FRET substrate for MMP 2&9. No significant reduction of MMP activity was seen 
when the development buffer was supplemented with any of the three chelating agents, 
indicating that Zn2+ required for MMP activity was not chelated from solution (Figure 4-
2). 
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Figure 4-2: MMP activity by chelation of Zn2+measured using specific FRET substrates 
for MMP 2&9.  
 
 Discussion 
 In this pilot study, we tested the efficacy for three different chelating agents known 
for their affinity of Ca2+ to compare their calcium demineralization potential. 
Demineralization of Ca2+ from HA shows that EGTA and BAPTA are not as effective in 
dissolving Ca2+ ions as EDTA. Reduction of MMP activity by chelation of Zn2+ was not 
observed with any of the three chelating agents. Although more studies are needed to 
confirm better demineralization of calcium deposits with different chelating agents, 
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including testing with Magnesium-based deposits (e.g., Whitlockite), calcified elastin 
fibers, and lesions. For now, EDTA was the chelator of choice. 
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5 SPECIFIC AIM 2 
TO INVESTIGATE WHETHER EDTA, A CHELATING AGENT, LOADED 
NANOPARTICLES CAN BE TARGETED TO SITES OF ELASTIN-SPECIFIC 
MEDIAL ARTERIAL CALCIFICATION AND WHETHER THE 
CALCIFICATION CAN BE REVERSED IN A RENAL FAILURE MODEL IN 
RATS 
 
 Introduction 
 Patients with chronic kidney disease (CKD) have an elevated burden of 
cardiovascular disease (CVD) and compared to age-matched individuals with normal renal 
function[76, 254], are more likely to die due to CVD than to progress to renal failure.  
Although a cause of such excessive cardiovascular mortality has not been singled out, a 
major contributing factor is thought to be vascular calcification [76, 255]. 
 Current therapies to treat VC, particularly in CKD, predominantly consist of 
controlling the mineral disturbance and are mainly preventive in action [256, 257]. EDTA 
is a promising chelating agent that can dissolve and remove calcium deposits if delivered 
near the calcification[258]. We demonstrated earlier that elastin antibody-conjugated NPs 
can be targeted to calcification sites and that EDTA delivered by these NPs reverses elastin-
specific MAC in a rat model of CaCl2 injury[259]. However, in that study, the aortic injury 
was created locally through a chemical insult, and systemic abnormalities usually 
associated with diseases like renal failure were not present. 
 Several research groups have employed the adenine-induced model of uremia and 
renal failure to characterize and investigate treatment methods for vascular calcification 
[159, 177, 179]. All these studies showed a common limitation that up to 50% of the rats 
fed with adenine diets do not show medial calcification in spite of a stable and comparable 
70 
 
CKD. Price et al. introduced a variant to this model by lowering the amount of protein in 
the diet to 2.5% and higher amounts of P than in a standard rodent diet[157].   Renal 
pathology of this model mimics the clinical situation with the development of 
hyperphosphatemia, hypocalcemia, severe secondary hyperparathyroidism, and other 
biochemical changes such as elevated serum creatinine and elevated blood urea nitrogen 
that lead to vascular calcification. Hence, this model is considered a useful tool to study 
complications of arterial calcification in CKD patients and to evaluate therapeutic agents 
in the prevention of uremia-related MAC[176, 260].  
 In the present study, we used the adenine diet with high P and high Ca-induced 
CKD rat model to test if albumin NPs loaded with EDTA delivered systemically would 
target calcific sites and remove vascular mineral deposition without the side effects 
associated with systemic EDTA chelation. 
 Materials and Methods  
 Preparation of BSA DiR Nanoparticles for in vivo targeting studies  
 DiR (1, 1-dioctadecyl-3, 3, 3, 3-tetramethylindotricarbocyanine iodide) (PromoCell 
GmbH, Heidelberg, Germany) loaded bovine serum albumin (BSA) (Seracare, Milford, 
MA) nanoparticles were prepared using desolvation method and conjugated to an anti-
elastin antibody (US Biological, MA, USA) for targeting purposes as described [247]. 
Briefly, 250 mg of BSA was dissolved in 4 mL of DI water.  25 mg of DiR dye dissolved 
in acetone was added to BSA solution and stirred for one hour at room temperature 
following the addition of glutaraldehyde (EM grade 70%, EMS, PA, USA) at a 
concentration of 42 µg/mg BSA. The mixture was added dropwise to 24 mL of ethanol 
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while sonicating (Omni Ruptor 400 Ultrasonic Homogenizer, Omni International Inc, 
Kennesaw, GA) on ice for 30 minutes. Nanoparticles thus obtained were separated by 
centrifugation and washed. These particles were PEGylated (DSPE-PEG (2000) 
Maleimide) (Avanti Polar Lipids, Inc., Alabaster, AL) and conjugated to anti-elastin 
antibody following a previously described protocol [245, 246].  
 Preparation of EDTA-loaded nanoparticles for treatment 
 EDTA-loaded NPs were obtained by dissolving 200 mg of BSA (Seracare, MA) 
and 100 mg of EDTA (Fisher Scientific, NJ) in 4 mL of deionized water and pH was 
adjusted to 8.5 with 6N NaOH. The aqueous solution was added drop-wise to 16 mL of 
ethanol under probe sonication for 1 hour. For crosslinking, glutaraldehyde at ten µg per 
mg of BSA was added during sonication. The elastin antibody was conjugated in a method 
similar to the DiR NPs [245].   
 Experimental renal failure in rats – Adenine rat model   
 Renal failure was induced in rats by feeding adenine diets having high P and Ca 
levels. High adenine feeding resulted in crystallization of 2,8-dihydroxyadenine in renal 
tubules and interstitial spaces, thereby causing nephritis, fibrosis and all metabolic 
anomalies associated with chronic renal failure [176, 260]. Male Sprague-Dawley rats 
(Charles River Laboratories) were fed standard diets containing 18% protein until their 
body weights were close to or exceeding 300g. Animals were then fed a customized 
adenine (0.75%) diet (Harlan Teklad, Madison, WI, USA) made of 2.5% protein along with 
higher levels of calcium and phosphorus (1.06% and 0.92% respectively) [157]. Rats were 
maintained on this diet for 28 days while their body weights and behavior were carefully 
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monitored. If the weight loss was found to be more than 20% of baseline body weight, 
adenine diet was replaced with rat chow for all the adenine diet-fed animals to maintain 
consistency and allow them to recover their weights.  Adenine diets were reintroduced once 
the animals recovered their weight, and the total adenine diet feeding time was 28 days. 
Control rats were fed normal chow diets without adenine for the length of the experiment. 
Disease progression in live animals was monitored via high-frequency ultrasound imaging 
(Vevo2100, VisualSonics, Toronto, Canada). Clemson University Animal Research 
Committee approved all animal use protocols (AUP) for the experimental models. All 
animals receive humane care in compliance with NIH Public Law 99-158, November 20, 
1985, “Animals in Research,” revised in 2015. 
 Targeting and Biodistribution of NPs 
 After 28 days of adenine diet feeding, six rats were injected with elastin antibody 
conjugated and DiR-loaded NPs via the tail vein. 24 hours later, the rats were euthanized 
and organs harvested for further analysis. Serum was collected for biochemical analysis 
using a standard autoanalyzer. The entire body and individual organs were imaged using a 
Caliper IVIS Lumina XR (Hopkinton, MA) with Ex/Em of 745/795 nm to calculate 
percentage fluorescence and targeting NPs to the site of injury in the aorta. Percentage 
Fluorescence was then calculated using the equation: 
 
%Fluorescence =  �
fluorescence in tissue
total fluorescence in all organs 
𝑇𝑇ℎ𝑒𝑒 𝑑𝑑ry weight of tissue  � *100%  
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 Treatment with EDTA nanoparticles and intravenous EDTA solution 
 For the treatment study, rats were fed adenine diets for 28 days and divided into 
five groups randomly (n=6 per group). The first group of rats received tail vein injections 
of PBS to act as a no-treatment control (Saline-IV). The second group of rats received tail 
vein injections of blank BSA NPs without EDTA but conjugated with anti-elastin antibody 
suspended in PBS as controls (Blank-NPs). The third group of rats was given intravenous 
injections of EDTA solution (EDTA-IV) in PBS twice a week for two weeks at a dosage 
of 3mg/kg body weight. The fourth group received tail vein injections of NPs loaded with 
EDTA and conjugated with anti-elastin antibody suspended in PBS twice a week for two 
weeks (EDTA-NPs). The last group received EDTA-NPs and was allowed to survive for 
four weeks after treatment (EDTA-NPs-LT). Animals were euthanized by exsanguination 
while under isoflurane, aortas (from the arch to the iliac bifurcation) were collected as a 
unit and fixed in 10% neutral buffered formalin. Other organs including kidneys, hearts, 
liver, spleen, and lungs were also harvested. Serum was collected from animals of all the 
groups for biochemical analysis. The complete schematic of the present study is elucidated 
in Figure 4-1.  
 Whole-mount aorta alizarin red S staining 
 The whole aortic tree from ascending aorta to iliac bifurcation was carefully 
cleaned of adherent tissues and soaked in freshly made 2% alizarin red solution (pH 4.1-
4.3) for 10 minutes and washed with DI water for ten more minutes. The aortas were then 
imaged by the stereomicroscope (Leica M125 stereo microscope, Leica Microsystems Inc. 
Buffalo Grove, IL). 
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Figure 5-1: Schematic representation of Specific Aim 1 study design. 
 
 
 Histology of aorta and kidneys 
 Aortas and kidneys were fixed in buffered formalin, embedded in paraffin and 
sectioned per standard procedures. Five-micrometer sections were mounted on positively 
charged glass slides. Slides were baked overnight at 56°C in an oven to adhere tissues to 
the slides and melt the paraffin. Subsequently, the slides were deparaffinized with xylenes 
followed by dehydration with graded ethanol. Aorta slides were stained with hematoxylin 
and eosin for overall tissue morphology, Verhoeff-van Gieson (VVG) for elastin fibers and 
Von Kossa stain with neutral fast red counterstain for calcium deposits. Kidney slides were 
stained with hematoxylin and eosin for morphology, Periodic acid-Schiff stain (PAS) for 
polysaccharides and mucosubstances, and with trichrome for muscle and collagen. 
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 Immunohistochemical analysis of the aorta 
 Aortas fixed in formalin were embedded in paraffin and sectioned as described 
earlier. Subsequently, xylenes and graded ethanol were used to deparaffinize the sections, 
and heat-induced antigen epitope retrieval was performed using citrate buffer (Thermo 
Scientific, MA). The slides were then incubated overnight at 4°C with primary antibodies 
— Mouse anti-Rat Alpha Smooth Muscle Actin (Biolegend, San Diego, CA), Rabbit anti-
Rat Caspase-3 (Cell Signaling Technology, Danvers, MA), Rabbit anti-Rat MMP-2 and 
Rabbit anti-Rat MMP-9 (Enzo Life Sciences, NY). Staining with relevant secondary 
antibodies was completed using IHC kit (Enzo Life Sciences, NY). Slides were visualized 
by either 3,3´-Diaminobenzidine (DAB) or 3-Amino-9-ethylcarbazole (AEC) chromogens 
followed by an appropriate counterstain. 
 Quantification of aortic calcium 
 Calcium content in the aortas was measured after lyophilizing the part of the tissue 
at renal bifurcation that showed some alizarin red S stain in the whole mount. The 
lyophilized tissue was hydrolyzed in 6N HCl at 95°C and dried under a continuous stream 
of nitrogen for about 45 minutes. The residue was subsequently reconstituted in 0.01N 
HCl, and samples were analyzed using the Spectro Acros ICP Spectrometer (SPECTRO 
Analytical Instruments, Kleve, Germany) at Clemson University Agricultural Service 
Laboratory. 
 Ultrasound analysis of the aorta 
 A high-frequency ultrasound machine (Vevo2100, VisualSonics, Toronto, Canada) 
was used to image and monitor the aortas of the rats at different time intervals by utilizing 
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a linear array probe (MS 400D, frequency 18-38MHz). While being imaged, the animals 
were given light anesthesia by inhalation of 2% isoflurane and were placed in the supine 
position on the imaging table. Aortic stiffness parameters circumferential strain and pulse 
wave velocity (PWV) were calculated from the M-Mode and EKV images obtained with 
the scans, respectively. 
 Circumferential Green-LaGrange strain was calculated with the assumption that the 
strain is uniform around the vessel using the equation given below 
 
𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝑒𝑒𝐶𝐶𝑒𝑒𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶 𝑆𝑆𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶 = 12 �� 𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐶𝐶𝐷𝐷𝐶𝐶𝐶𝐶𝐶𝐶𝐷𝐷𝑑𝑑𝐶𝐶𝐶𝐶𝐷𝐷𝐶𝐶𝐷𝐷𝐶𝐶𝐶𝐶𝐶𝐶�2 − 1� ∗ 100 
 
 Bone integrity as evaluated by micro CT scanning 
 Femoral bones harvested from the rats were wrapped with parafilm to prevent 
drying and scanned using a high performance in vivo micro CT scanner (Skyscan 1176, 
Bruker BioSpin, Billerica, MA). Reconstruction was carried out employing a Feldkamp 
algorithm using the built-in Skyscan Nrecon software. Functional mechanical testing of 
bone was performed on the rat femurs using a Bose test instrument (Electroforce 3200, 
Bose, MN, USA) and exposing them to escalating forces until fracture.  At fracture, 
maximum load (N) was determined. 
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 Statistics 
 All the results, including graphs in the figures, are given as mean±S.D. Statistical 
analysis was performed using a one-way analysis of variance (ANOVA). Results were 
considered to be significant when p-values ≤0.05. Tukey’s HSD was then used post-hoc to 
identify the treatment groups with a significant difference. 
 
 Results 
 Nanoparticle preparation and characterization 
 EDTA-loaded NPs were prepared based on the procedure described previously our 
laboratory. They were then characterized by TEM and particle size analyzer for size and 
surface zeta potential. NPs had a final average size of 254.42±31.8nm; Zeta potential of 
the NPs was measured as -24.42±4.49mv. The average yield of NPs after centrifugation 
was 53.18±1.50%. EDTA loading into the NPs was 25.88±0.172% (Figure 5-2 A). EDTA 
was released from these particles over a period of 72 hours (Figure 5-2 B). 
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Figure 5-2: EDTA NPs characterization and release kinetics. (A) TEM Imaging for NP 
particle size. Table below the TEM shows average particle size, surface zeta potential, 
average final yield of NPs and drug loading percentage. (B) In vitro EDTA release from 
NPs.  
 
 Adenine-induced renal failure model 
 Rats were fed adenine diets containing higher phosphate and calcium for 28 days 
to induce renal failure and vascular calcification. Body weights measured during the 
experiment indicated that the adenine diet-fed rats lost weight, possibly due to malnutrition 
and starvation (Figure 5-3). Modulating the adenine diet feeding, as explained in the 
methods section, enabled us to eliminate possible mortality in this model. All the animals 
survived until the end of the study, at which time they were electively euthanized.  
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Figure 5-3: Body weights of rats monitored during adenine-diet feeding. 
 Morphology of kidneys and serum biochemistry 
 Harvested kidneys from the adenine-fed rats showed extensive morphological 
damage with crystal deposition in comparison to a standard diet-fed kidney (Figure 5-4 A). 
Histology of kidneys from adenine-fed rats revealed increased infiltration of inflammatory 
cells and fibrosis. Structural changes were severe and predominant in these rats validated 
by increased vacuolation of tubules, tubular atrophy, and an increased number of tubules 
with cell debris (Figure 5-4 B). Induction of CKD was further evidenced by higher serum 
creatinine and blood urea nitrogen (BUN) concentrations in the adenine-fed rats compared 
to normal animals. Furthermore, these animals also exhibited high serum phosphate and 
uric acid concentrations (Table 5-1).   
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Figure 5-4: Morphology and histology of rat kidneys. (A) Gross morphological images of 
normal diet- and adenine diet-fed kidneys. (B) Histological staining of kidneys in normal- 
and adenine diet-fed kidneys – H&E (b1-b2), Periodic acid-Schiff (b3-b4), and Masson’s 
trichrome (b5-b6).  
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Table 5-1: Serum biochemistry of adenine-fed rats (n=6 per group) 
 Normal diet  Adenine diet  
 
Serum Creatinine 
(mg/dL) 
 
0.25±0.11 2.79±1.30* 
Serum Phosphate 
(mg/dL) 7.58±0.25 11.42±4.34* 
 
Serum Calcium 
(mg/dL) 
 
10.00±0.29 
 
10.27±0.42 
 
BUN (mg/dL) 
 
15.50±1.50 
 
53.34±10.09* 
 
Uric Acid (mmol/L) 
 
0.73±0.12 
 
1.44±0.15* 
 
GFR 
 
>60 
 
15.34±4.11 
*  represents statistical significance (Student’s unpaired t-test, p < 0.05) 
 
 Organ distribution of NPs and targeting to damaged aorta 
 Elastin antibody conjugated and DiR dye loaded NPs were injected through the tail 
vein of the rats after 28 days of feeding adenine. The NPs targeted the calcified and 
degraded aortic elastic lamina sites within 24 hours while sparing the healthy regions of 
the aorta in 4 out of 6 rats injected with DiR-NPs, which correlated with elastin damage. 
Animals that were fed normal diets did not show any targeting of the NPs to the aorta 
(Figure 5-5 A). The percentage fluorescence intensity normalized to the tissue weight for 
various organs showed 69.16±14.27% targeting of NPs to the calcification sites (Figure 5-
5 B). Representative histological sections of the aortas showed that there was indeed 
degraded elastic lamina in the medial layers of the aorta as shown by VVG staining (Figure 
5-6 a1-b1) and calcification of the damaged/degraded elastic lamina as shown by von 
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Kossa staining (Figure 5-6 a2-b2). NPs loaded with DiR dye were infiltrating the 
calcification site through adventitia in the adenine fed rats and reached the medial 
calcification sites (Figure 5-6 a3-b3).   
 
Figure 5-5: Nanoparticle targeting to diseased rat aortas (n=6). (A) NP accumulation in 
aorta following systemic IV injection of EL-DIR-NPs. (B) Organ distribution of NPs as 
measured by fluorescence intensity on iVIS imaging system.  
 
 
Figure 5-6: Histology of the aortas in adenine diet- and control diet- fed rats (n=6 per 
group).  
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 Targeted EDTA Chelation Therapy leads to reversal of calcification 
 Quantitative calcium content of the aortic tissues showed the highest calcium 
content (13.47±3.5 µg/mg of the aorta) in intravenous saline (Saline-IV) group. There was 
a slight decrease in systemic intravenous EDTA (EDTA-IV) group (9.82±3.3% µg/mg), 
but the decrease was not statistically significant. EDTA-loaded targeted NPs (EDTA-NPs) 
group showed the least calcium content (6.4±3.2% µg/mg). This was significantly different 
from the Saline-IV group, which was further reduced in EDTA-NPs-LT group suggesting 
that removal of calcification continued even after NP therapy was halted (Figure 5-7). 
Aortic calcification evaluated by stereomicroscopic images of alizarin red-stained whole 
aortas corroborated the quantitative calcium results. Rats treated with EDTA-NPs and 
EDTA-NPs-LT showed significant elimination of the calcific spots, suggesting a reversal 
of mineral deposition (Figure 5-8 A: a4, a5). Representative histology of the aortas stained 
with von Kossa stain showed pronounced calcification of the medial layer in the Saline-IV 
and Blank-NP groups (Figure 5-8 B: b1, b2). This was to some extent reduced in aortas 
treated with EDTA-IV (Figure 5-8 B: b3), but it was completely absent in EDTA NPs and 
EDTA-NPs-LT groups, clearly suggesting that EDTA-removed calcium deposits and 
calcification did not return even after EDTA treatment was stopped for four weeks (Figure 
5-8 B: b4, b5). 
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Figure 5-7: Quantification of calcium in the aorta of all the treatment groups. (n=6). (*, 
p<0.05, One –way ANOVA with Tukey’s HSD). Solid line represents mean value.  
 
 
 
Figure 5-8: Histological staining of aorta for calcification in all the treatment groups. (A) 
Whole mount aortas stained with alizarin red S to visualize calcium. (B) Cross-sections of 
aortas stained with von Kossa stain for Ca deposits. 
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 Serum biochemistry following EDTA nanoparticle treatment 
Serum biochemistry measurements following chelation therapy show reduced 
creatinine and P levels in all the groups, including the Saline-IV and Blank-NP groups. 
This may be due to the adenine diet being discontinued during therapy. BUN, Uric Acid, 
however, remained high in all the groups. No morphological of histopathological 
differences were seen in kidneys from all the treatment groups compared to kidneys from 
adenine-fed rats before the treatment (Table 4-2). 
 
Table 4-2: Serum biochemistry following chelation therapy. (n=6 per group). 
 
 Saline-IV  
 
Blank-NPs 
 
EDTA-IV  EDTA-NPs  EDTA-
NPs-LT 
 
Serum 
Creatinine 
0.53±0.10 0.70±0.23 0.63±1.1 0.73±0.26 0.46±0.00 
Serum 
Phosphate 
8.46±0.54 8.66±0.46 8.62±0.48 7.95±0.88 8.10±0.50 
Serum 
Calcium 
10.167±0.24 10.333±0.359 10.15±0.3 10.30±0.30 10.36±0.23 
BUN 30.167±3.1 31.66±7.63 36.50±5.85 46.16±14.53 25.80±5.11 
Uric Acid 1.62±0.18 1.58±0.34 1.42±0.21 1.317±0.2 1.26±0.1 
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 Immunohistochemical analyses of the aorta for SMC phenotype and 
MMPs 
Staining for alpha-smooth muscle actin indicated the loss of SMCs in the Saline-
IV group due to calcification compared to a normal diet-fed control rat (Figure 5-9 A: a1, 
a2). SMC staining increased significantly in the EDTA-NPs and EDTA-NPs-LT groups, 
indicating that the removal calcification allowed restoration of SMC phenotype in the 
medial layer (Figure 5-9 A: a3, a4). To explore if the loss of VSMCs was because of 
apoptosis, Caspase-3 staining with 3,3´-Diaminobenzidine chromogen was performed. 
Caspase-3 marker was not detectable in a normal diet-fed rat, and it increased around the 
calcific sites in Saline-IV group (Figure 5-9 B: b1, b2). Apoptotic activity was considerably 
reduced in EDTA NPs and EDTA-NPs-LT groups, clearly suggesting that apoptotic cells 
were replaced by healthy cells (Figure 5-9 B: b3, b4).  
 
 
Figure 5-9: Immunohistochemical staining of the aortas for VSMC status in the treatment 
groups. (A) Representative images of IHC staining for anti-alpha smooth muscle actin. (B) 
IHC staining for caspase-3 showing apoptotic activity. (Insets in each image show 
respective secondary antibody controls). 
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Anti MMP-2 staining showed that MMP-2 activity was present in the calcified 
regions of the aorta in Saline-IV with no detectable MMP activity in a normal diet-fed rat 
(Figure 5-10 A: a1, a2). Treatment with EDTA-NPs slightly reduced MMP-2 activity, 
while EDTA-NPs-LT group showed the absence of MMP-2 staining in the medial layers 
(Figure 5-10 A: a3, a4).  Staining for MMP-9 also was present in the calcified regions of 
the medial layers of the adenine diet-fed rat aortas in Saline-IV and absent in a normal rat 
aorta (Figure 5-10 B: b1, b2). MMP-9 activity was significantly reduced in both the EDTA 
NP treatment groups –EDTA-NPs and EDTA-NPs-LT (Figure 5-10 B: b1, b2). 
 
 
 
Figure 5-10: Immunohistochemical staining of the aortas for matrix metalloproteinases 
(MMPs) in the treatment groups. (A) Representative images of IHC staining for MMP-2. 
(B) IHC staining for MMP-9. (Insets in each image show respective secondary antibody 
controls).  
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 In vivo ultrasound imaging 
Ultrasound images of abdominal aortas were obtained during adenine diet feeding 
and after therapy. Healthy aortas from standard chow-fed rats showed thin and elastic 
aortas. In rats fed with the adenine diet, substantial calcification was seen in the medial 
layer of the abdominal aorta (Figure 5-11 A: a1, a2). Among the treatment groups, 
calcification was observed to be noticeably reduced only in the EDTA-NPs group; the 
Saline-IV, Blank-NPs and EDTA-IV groups all showed the persistence of calcification 
(Figure 5-11 A: a3 – a6). Circumferential strains of the healthy aortas, as calculated from 
the Green-LaGrange strain equation, were 11.99±1.043% (n=6). Strains in the rats fed with 
adenine diet for 28 days showed decreased circumferential strains, suggesting stiffening of 
the artery due to aortic mineralization. Saline-IV, Blank-NPs, and EDTA-IV groups did 
not reduce calcification; thus, aortic stiffness remained unimproved. Only EDTA-NPs 
group showed a statistically significant improvement in circumferential strain 
(9.22±1.05%) compared to the rest of the groups, suggesting that removal of the mineral 
content led to more elastic aortas (Figure 5-11 B).  
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Figure 5-11: In vivo ultrasound imaging of the rat aortas. (A) Representative 2D B-mode 
images from control and all treatment groups. (B) Circumferential strain, as calculated 
from Green-LaGrange equation using M-Mode images. (n=6). (*, p<0.05, One –way 
ANOVA with Tukey’s HSD). Solid line represents mean value 
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 Bone morphology and functional testing 
Representative 2D-image from micro CT scans of the femurs about 10 mm below 
the trochanter revealed reduced mineralization in all the groups. EDTA-NPs group did not 
show any additional reduction in mineralization compared to any other group fed with 
adenine diet, indicating that EDTA NPs did not cause structural damage to the bone (Figure 
5-12 a). Functional studies on bone stability indicated that the maximum load needed to 
fracture the femurs did not differ significantly among the four treatment groups. This 
confirmed that bone stability was not affected by EDTA-NPs treatment (Figure 5-12 b). 
 
Figure 5-12: Morphology and functional testing of rat femurs from all the treatment 
groups. (a) Representative two-dimensional slices from microcomputed tomography of rat 
femurs from the different treatment groups. (b) Maximum load before breaking for femoral 
bone in the treatment groups. 
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 Discussion 
 In this aim, our goal was to test whether elastin-specific MAC could be reversed by 
targeted EDTA chelation therapy in a clinically relevant model of CKD.  To our 
knowledge, we, for the first time demonstrated that targeted nanoparticles injected 
systemically could target the calcified arteries and remove calcification in a CKD model in 
rats despite altered blood biochemistry.  
  Over the last few years, several research groups have made use of the 
adenine model for studying mechanisms of MAC in CKD [157, 175, 178, 260-262]. We 
were able to successfully induce CKD in rats fed with 0.75% adenine supplemented by 
high concentrations of Ca and P. Along with the expected structural damage to kidneys, 
biochemical abnormalities like elevated serum creatinine, serum phosphate, and higher 
levels of the BUN were seen. This closely resembled CRF in humans, making the model 
useful for the study of our targeted chelation therapy.  
 Several research groups have reported that one of the chief limitations of the 
adenine model is that a small dose of adenine (0.2%) causes inconsistent calcification, and 
a high dose (0.75%) causes excessive mortality [176, 260]. In our studies, carefully 
controlled 0.75% adenine-feeding led to medial vascular calcification without undue 
mortality. Albumin NPs conjugated with elastin-antibody, which recognizes only damaged 
elastin in the vasculature, were used to deliver EDTA to the calcification sites in animals 
fed adenine diets. Fluorescence intensity of DiR dye-loaded animals showed accumulation 
of NPs at calcification sites. The healthy regions of the aorta in these animals and the entire 
aorta in the rats fed rat chow diets were spared, demonstrating that NPs targeted only 
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degraded elastin. In previous studies, we showed that nanoparticles conjugated with 
generic IgG antibody do not target damaged elastin site [245, 246, 248, 259], suggesting 
that our elastin antibody conjugation led to site specificity. NPs also accumulated in liver 
and spleen, possibly because they are taken up by Kupffer cells in the liver and due to 
reticuloendothelial clearance [263]. This is very common for many nanoparticle therapies 
[264, 265]. Moreover, we observed that the NPs entered the media from the adventitial side 
through the vasa vasorum [245, 246]. Such adventitial delivery is advantageous: Often, 
intraluminal thrombus or atherosclerosis can hinder particles targeted from the lumen side. 
 Having established targeting efficiency of NPs to the calcified sites, we proceed to 
test reversal of calcification by delivering EDTA-loaded NPs. We prepared albumin 
nanoparticles loaded with EDTA following an established procedure [259]. Previously, we 
showed that such nanoparticles release EDTA slowly over a period of 72 hours. Our 
previous studies also showed, both in vitro and in vivo, that when EDTA was delivered in 
proximity to calcific deposits, EDTA removed the calcification [258, 259].  In this study, 
we chose to inject NPs twice a week for two weeks based on the release profile for EDTA. 
We included systemic EDTA injections as controls, at a dosage similar to the chelating 
agent released from our nanoparticles. After the two weeks of injections, we observed that 
the EDTA-loaded NPs reversed calcium deposits in the rat arteries, as confirmed by in vivo 
ultrasound, whole-mount aorta alizarin red stain, histology with von Kossa stain, and 
quantitative calcium levels. When EDTA alone was injected systemically, calcification 
was reversed only slightly; therefore, multiple injections or a higher concentration of 
EDTA will be required to achieve reversal. That can lead to systemic side effects as shown 
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previously with systemic EDTA therapy[179, 266, 267]. As expected, when the rats were 
injected with saline only and blank NPs as controls, the calcium deposits were not removed, 
and aortas remained calcified and stiff. We checked the status of kidneys in all animals at 
the end of the therapy by measuring blood biochemistry (Table 4-2). As the adenine diet 
was not continued during the two-week therapy, we did find reduced creatinine and P levels 
in all groups (including Saline-IV and Blank-NP groups) while BUN, uric acid remained 
high. This showed that EDTA therapy did not affect kidney function. Stopping the adenine 
diet might have improved kidney function in all groups, but once vascular calcification 
developed, it did not regress as can be seen in saline and Blank-NP groups. We saw a 
significant reduction in vascular calcification only after targeted therapy. 
 Elevated MMPs have been reported to have a strong correlation with elastic fiber 
degradation, stiffness, and calcification. Particularly, MMP-2 and MMP-9 up-regulation 
have been associated with arterial stiffening in diabetic patients with CKD [268]. 
Immunohistochemical staining for MMP-2 and MMP-9 showed that both were indeed 
present in the calcified regions of the aorta in adenine-fed rats. This suggests that MMP-2 
and MMP-9 may be involved in elastin degradation and eventually causing elastin 
calcification in the adenine model. We showed that MMP-9 and MMP-9 knockout mice 
did not show vascular calcification in a CaCl2 injury model [131]. Significant reduction in 
both MMP-2 and MMP-9 after removal of calcification suggests that the inflammatory 
cascade is reversed after removal of calcification. It may be that locally delivered EDTA 
chelated Zn2+ ions required for MMP activity and inhibited MMPs as shown earlier by 
others[269, 270], but this needs to be studied in detail.  
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 We also evaluated cellular status in the aorta after adenine diet-induced 
calcification and after the therapy. Others showed that after adenine diet, SMCs lost 
phenotype and underwent apoptosis, and those apoptotic bodies aggravated calcification 
[94, 271]. In the in vivo studies described here, we saw the loss of SMC phenotype and 
increased apoptosis in cells close to medial calcification. Surprisingly, we found that after 
removal of calcification, there was an increase in SMC-type staining in the medial layers 
of the aorta. Further cell tracing studies are necessary to investigate if the higher SMCs 
seen after -treatment we due to dedifferentiation or repopulation by recruitment of HSCs, 
pericytes, or by EMT.  
 High-frequency ultrasound imaging helped us study changes to the aorta in vivo. It 
was shown that a reduced circumferential strain is an indicator of aortic stiffness[272]. 
Circumferential strains measured from M-mode images in healthy aortas were as reported 
in the literature. We observed that circumferential strain is reduced after adenine-diet 
feeding; this indicated increased aortic stiffness caused by calcification. EDTA NPs 
treatment removed calcium deposits and improved the circumferential strain levels, aortic 
elasticity, and health.  
 One important observation was that MMP activity and calcification did not return 
even after EDTA therapy was suspended for four weeks (EDTA-NP-LT group) although 
that CKD was present in the animals. EDTA targeted therapy did not cause any undue side 
effects in bone and mineral metabolism and biomechanics. Micro CT scanning to study 
bone morphology showed reduced mineralization in all groups. This was expected, as 
uremia is associated with reduced bone mineral density [179]. EDTA NPs group showed 
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no additional reduction in mineral density when compared to the Saline-IV and the Blank-
NPs group. We showed earlier that polyphenols such as PGG, when delivered with 
nanoparticles, do regenerate degraded aortic elastin [247]. Thus, there is an exciting 
opportunity of dual nanoparticle therapy to first remove calcium deposits using EDTA and 
then restore medial elastin layers with PGG.   
 In conclusion, we demonstrated that targeted delivery of minimal doses of EDTA 
is an effective way to reverse calcification in an experimental rat model of CKD. This 
establishes the enormous potential for targeted EDTA chelation therapy as a viable clinical 
alternative to reverse vascular calcification in CKD patients. 
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6 SPECIFIC AIM 3 
 
TO ESTABLISH AND VALIDATE ADENINE-INDUCED CKD MODEL OF 
MEDIAL ARTERIAL CALCIFICATION IN MICE BY MONITORING DISEASE 
PROGRESSION IN VIVO AND EXPLORING VSMC STATUS FOR POTENTIAL 
USE IN INVESTIGATING TARGETED EDTA CHELATION THERAPY AND 
EFFECT OF REVERSAL OF CALCIFICATION ON VASCULAR 
HOMEOSTASIS AND FUNCTION.  
 
 Introduction 
 In our studies with adenine model in rats, the animals were placed back on the 
standard diet during the course of chelation therapy after renal failure was established and 
calcified manifested. We do not know at this point if persistence of high circulating levels 
of Ca and P due to continuing adenine diet will result in return of calcification. There is a 
likelihood that the degraded elastin and calcium-binding sites will remain open after 
chelation and calcification may return in due course.  
 Moreover, our laboratory and several other research groups have shown that 
VSMCs begin to undergo osteogenic differentiation with transformation into osteoblast-
like cells during the process of calcification [273, 274]. VSMC phenotypic alteration is 
accompanied by increased expression of proteins associated with bone such as Osteocalcin 
(OCN), Osteopontin (OPN), Runt-related transcription factor (RUNX-2), Bone 
morphogenic protein-2 (BMP-2) and increased Alkaline phosphatase (ALP) activity [79, 
275, 276]. Increased levels of Ca and P levels, as seen in CKD patients, may accelerate 
mineral deposition and result in early calcification around elastin fibers [275]. More 
recently, we have shown that osteogenic transdifferentiation of VSMCs occurs when 
cultured on surfaces of HA and calcified elastin [273]. Remarkably, when cells were 
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removed from the calcific environment and returned to normal culture, they revert to their 
VSMC phenotype [274]. However, the feasibility of this phenotypic reversal of VSMCs, 
once the calcification is removed, in vivo remains unseen and open to investigation.  
 It would be intriguing to explore whether reversal of calcification through targeted 
EDTA chelation therapy can revert this expected phenotypic transformation of VSMCs in 
vivo. Our imminent goal is to investigate this phenomenon in an animal model of MAC 
caused by CKD. To test this hypothesis, extensive cell lineage tracing studies are needed 
to examine smooth muscle cell fate during calcification and after therapy. Mice present the 
possibility of genetic manipulation, thus offering avenues to inspect cellular and molecular 
mechanisms of disease progression and therapeutic effects in detail.  
 In the current aim, we sought to establish and validate the adenine-induced CKD 
model of MAC in mice in our laboratory for monitoring the progression of calcification in 
vivo and to explore VSMC status in calcified aortas. Our primary objective was to target 
our nanoparticle delivery system to diseased regions of calcified aortas in mice for potential 
delivery of chelating agent EDTA and therapeutics. We further studied global gene 
expression profiles of VSMCs to ascertain transdifferentiation into osteogenic phenotype. 
This model will provide a basis for investigating if targeted EDTA chelation therapy can 
restore VSMC cellular status and reinstate vascular homeostasis. 
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 Materials and methods 
 Adenine-induced renal failure in mice 
 Six- to eight-week old mice with C57BL/6J genetic background (Jackson 
Laboratories) were housed in standard cages with wood chip bedding and paper roll for 
enrichment at ambient temperature (21-22°C) in a 12-hour light cycle. Mice were allowed 
to acclimatize to the conditions of the animal facility for a period of 7 days before the start 
of the experiment. For adenine-rich feeding, customized diets were purchased (Envigo 
Teklad, Madison, WI, USA). A 0.2% adenine diet was formulated to have similarities to 
the ones described in literature with 20% casein to make the diet more palatable for the 
mice, containing 0.9% P and 0.6% Ca. A high phosphate containing diet was also 
formulated with 20% casein, 0.6% Ca but with a 1.8% concentration of P. The mice were 
fed with the 0.2% adenine diet for a period of 4 weeks to induce CKD followed by 0.2% 
and high P diet for a further 4 weeks to produce arterial calcification (Ade+hP). The second 
group of mice was fed the 0.2% adenine and 0.9% P diet throughout the length of the study 
(Ade+nP). Animals were monitored regularly for expected loss of body weight and diets 
were intermittently switched to standard chow diet to allow weight recovery, resulting in 
zero unexpected mortality. Control group mice were fed standard chow diet throughout.  
 In vivo micro CT scan 
 A desktop in vivo X-ray micro-CT system (Skyscan 1172, Bruker Biospin) was 
used to obtain micro-CT images. With this system, both the X-ray source and the detector 
rotate around the animal. The mice were anesthetized with inhalation of isoflurane. A 0.2µ 
aluminum filter and a 90 kV tube voltage with an exposure time of 200ms were chosen as 
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the in vivo scanning parameters. Animals were placed on their back in the bed of scanner, 
and images were obtained at 18µm resolution with a rotational step of 0.7°. These settings 
allowed us to scan the axial length of the thorax in ~20 times of total exposure time. 
Transverse, Coronal, and Sagital virtual cross-sections were reconstructed by Feldkamp 
cone-beam algorithm using the in-built NRecon software. Finally, 3D models of 
reconstructed aortic scans were created by segmenting them out from other bodily tissues 
and fluids using a set of operations provided on the CTAn software.  
 Ultrasound imaging of aortas in vivo 
 Mice were scanned with a high-frequency ultrasound machine (Vevo2100, 
VisualSonics, Toronto, Canada) to image and monitor their aortas at regular time points 
during the study by utilizing a linear array probe (MS550D, frequency 22-55 MHz). 
Animals were placed in the supine position on the imaging table and anesthetized during 
scanning through inhalation of 2% isoflurane. Aortic stiffness parameters circumferential 
strain and pulse wave velocity (PWV) were calculated from the M-Mode and PW (Pulsed-
wave) Doppler mode images obtained with the scans, respectively. 
 Measurement of aortic circumferential strain  
 Circumferential Green-LaGrange strain was calculated with the assumption that the 
strain is uniform around the vessel using the equation given below  
𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝑒𝑒𝐶𝐶𝑒𝑒𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶 𝑆𝑆𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶 = 12 �� 𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐶𝐶𝐷𝐷𝐶𝐶𝐶𝐶𝐶𝐶𝐷𝐷𝑑𝑑𝐶𝐶𝐶𝐶𝐷𝐷𝐶𝐶𝐷𝐷𝐶𝐶𝐶𝐶𝐶𝐶�2 − 1� ∗ 100 
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 Measurement of local pulse wave velocity (PWV) 
 Local PWV measurement made on a short segment of an artery can work as an 
early diagnostic tool to identify local stiffness of the arterial wall. PWV velocity at several 
short segments of the aorta was calculated indirectly using the parameters obtained from 
Color Doppler and PW Doppler mode images using the formula: 
 
𝑃𝑃𝐶𝐶𝐶𝐶𝐷𝐷𝑒𝑒 𝑊𝑊𝐶𝐶𝑊𝑊𝑒𝑒 𝑉𝑉𝑒𝑒𝐶𝐶𝐷𝐷𝐶𝐶𝐶𝐶𝐶𝐶𝐷𝐷 (𝑃𝑃𝑊𝑊𝑉𝑉) = 𝐷𝐷
∆𝑇𝑇
  
  
 where  𝐷𝐷 is the distance between two points along the aorta traveled by the pulse 
wave and ∆𝑇𝑇 is the transit time or time delay between the two points. Time from the R 
wave on the ECG to the ‘foot’ of the Doppler waveform is calculated for the two points 
and the difference is recorded as transit time.  
 Targeting and Biodistribution of NPs 
 At the end of customized diet feeding in all the three groups, mice were injected 
with DiR-loaded and elastin antibody conjugated (ELN-DiR-NPs) via the tail vein. 24 
hours later, the mice were euthanized, and organs harvested for further analysis. Serum 
was collected for biochemical analysis using a standard autoanalyzer. The entire body and 
individual organs were imaged using a Caliper IVIS Lumina XR (Hopkinton, MA) with 
Ex/Em of 745/795 nm to calculate percentage fluorescence and targeting NPs to the site of 
injury in the aorta. Percentage Fluorescence was then calculated using the equation: 
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 %Fluorescence =  �
fluorescence in tissue
total fluorescence in all organs 
𝑇𝑇ℎ𝑒𝑒 𝑑𝑑ry weight of tissue  � *100%  
 
The overall design of the study is illustrated in Figure 6-1. 
 
 
Figure 6-1: Schematic diagram of the adenine mice study. (n=6 per group per experiment). 
 
 
 Alizarin red staining of the whole mount aortas 
 Briefly, whole aortas were carefully cleaned of adherent tissues and soaked in 
freshly made 2% alizarin red solution (pH 4.1-4.3) for 10 minutes and washed with DI 
water for 10 more minutes. The aortas were then imaged by the stereomicroscope (Leica 
M125 stereo microscope, Leica Microsystems Inc. Buffalo Grove, IL). This will indicate 
regions of possible calcification on the aorta which are further analyzed as described next.  
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 Histology of kidneys  
 Kidneys were fixed in buffered formalin, embedded in paraffin and sectioned 
according to standard procedures. They were then stained with Hematoxylin and Eosin for 
overall morphology, Periodic acid-Schiff stain (PAS) for polysaccharides and 
mucosubstances, Trichrome for muscle and collagen. 
 Histology of aorta cross-sections 
 Segments of aortas from regions where DiR fluorescence was seen on the iVIS 
system were embedded Tissue Tek OCT compound, and 5 µm sections were mounted on 
charged slides by cryosectioning. Slides were fixed in cold acetone, air-dried at room 
temperature and then used for staining. The following histological stains were used: 
Hematoxylin and eosin (H&E) for overall tissue morphology, Alizarin Red with Light 
Green SF yellowish counterstain to detect calcification, von Kossa stain with neutral fast 
red counterstain for calcium deposits and Verhoeff-van Gieson (VVG) stain for elastin 
fibers.  
 Quantification of aortic calcium 
 Calcium content in the aortas was measured after lyophilizing a section of the whole 
aorta. The lyophilized tissue was hydrolyzed in 6N HCl at 95°C and dried under a 
continuous stream of nitrogen for about 45 minutes. The residue was subsequently 
reconstituted in 0.01N HCl, and samples were analyzed using the Spectro Acros ICP 
Spectrometer (SPECTRO Analytical Instruments, Kleve, Germany) at Clemson University 
Agricultural Service Laboratory. 
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 Immunohistochemistry for VSMC status 
 Briefly, OCT compound was washed off the tissue sections (5 μm), and they were 
placed in a water bath containing citrate buffer (10 mM Sodium Citrate, 0.05% Tween 20, 
pH 6.0) inside a pressure cooker to achieve heat-induced unmasking of antigens.  
Endogenous peroxidases were quenched with 3% hydrogen peroxide. Non-specific 
background was eliminated by treating the sections with Background Buster (Innovex) for 
1hr at RT. Primary Antibodies against were applied overnight at 4°C against Alpha smooth 
muscle actin (ACTA2) (Novus Biologicals, Centennial, CO), Smooth Muscle Myosin 
Heavy Chain (SMMHC), Runt-related transcription factor (RUNX-2) (Santa Cruz 
Biotechnology, Inc., Dallas, TX), Bone morphogenic factor-2 (BMP-2), Osteopontin 
(OPN) (Rockland). Following primary antibody incubation, relevant secondary antibodies 
were applied and signal was enhanced by ABC method (Vector, Burlingame, CA). Slides 
were visualized by either 3,3´-Diaminobenzidine (DAB) or NovaRed peroxidase substrate 
chromogens (Vector, Burlingame, CA) followed by a light hematoxylin counterstaining 
prior to mounting.  
 Clariom S microarray analysis for differential gene expression  
 Total RNA (miRNAeasy Micro Kit, Qiagen) was prepared using aortas isolated 
from adenine+hP and control group mice. Purified RNA was labeled with the help of a 
GeneChip Wash and Stain Kit (Affymetrix, Santa Clara, CA), then hybridized to Clariom 
S Mouse Array (Affymetrix, Santa Clara, CA) according to manufacturer instructions. Data 
resulted in 22,206 detected probes that were used for subsequent analysis, and expression 
patterns are displayed as a heat map. 
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 Statistics 
 All the results, including graphs in the figures, are given as mean±S.D. Statistical 
analysis was performed using a one-way analysis of variance (ANOVA). Results were 
considered to be significant when p-values ≤0.05. Tukey’s HSD was then used post-hoc to 
identify the treatment groups with a significant difference. 
 
 Results 
 Body weights, serum biochemistry and histomorphology of kidneys 
 As a convention, mice fed the customized diets were monitored for loss of body 
weight caused due to starvation, daily quantities of water consumed and urine excreted. 
Mice fed the adenine containing diets lost weight at a steady rate (~20% over a period of 5 
days) (Figure 6-2). To avoid death of animals due to starvation and weight loss [277, 278], 
we modulated the feeding to allow for intermittent weight recovery when they reach 20% 
weight loss before placing them back on the adenine diets. As with the rats, this allowed 
us to eliminate mortality caused in mice due to this mode. Mice fed adenine-diets also were 
observed to consume higher quantities of water and passed higher amounts of urine when 
compared to the control diet-fed mice [279, 280] (data reported by animal housing facility 
and not shown due to the requirement of metabolic cage usage). Biochemical analyses 
performed on sera extracted from these mice suggest that severe dysfunction of kidneys is 
induced in these mice with reported increases in Serum Creatinine (2-fold), Serum 
Phosphorus (1.5-fold) and Blood Urea Nitrogen (BUN) levels (2.5 fold). (Table 6-1). 
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 In adenine-diet fed mice, discoloration and deformity of the kidneys were obvious 
after 28 days of adenine feeding compared to the control mice (Figure 6-3A). Renal 
histology in the adenine-diet fed mice shows deposition of crystalline structures in the 
tubular lumen and peritubular inflammatory cell infiltration alongside several dilated 
tubules (Figure 6-3 b1-b2). PAS staining showed dilated bowman’s spaces in some 
glomeruli, tubular atrophy, and thickened basement membranes (Figure 6-3 b3-b4). Severe 
tubulointerstitial fibrosis can be seen with Masson’s Trichrome stain (Figure 6-3 b5-b6). 
 
 
Figure 6-2: Body weights of the three groups of mice. 
 
 
 
 
 
0.00
5.00
10.00
15.00
20.00
25.00
30.00
35.00
0 14 28 42 56 70 84 98
W
ei
gh
t i
n 
g
Days
106 
 
Table 6-1: Serum biochemistry for renal function parameters in adenine-fed mice. 
 Control diet Adenine diet 
Serum Creatinine <0.17 0.40±0.10* 
Serum Phosphate 8.5±1.09 14.03±4.32* 
Serum Calcium 9.02±0.19 8.42±1.68 
BUN 19.6±3.2 49.43±12.74* 
Glucose 198.2±27.01 141.83±56.19 
GFR >60 >60 
 
* represents significant difference in adenine mice from control mice 
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Figure 6-3: Morphology and histology of kidneys in mice. (A) Gross morphological 
images of normal diet- and adenine diet-fed kidneys. (B) Histological staining of kidneys 
in normal- and adenine diet-fed kidneys – H&E (b1-b2), Periodic acid-Schiff (b3-b4), and 
Masson’s trichrome (b5-b6). (n=6 animals per group). Scale bar = 100µm. 
 
 In vivo Micro CT scanning for visualization of aortic calcification 
 Calcification of the aorta was evident on CT images of Ade+hP group mice. Three-
dimensionally scanned and reconstructed images visually confirmed presence of 
calcification in the aorta, mainly in the infrarenal region (Figure 6-4 A1-A3). However, CT 
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imaging performed on the same group of mice at their 28-day time point did not show any 
tangible calcification (data not shown) while images from Ade+nP group mice were devoid 
of any aortic calcification throughout the duration of the feeding (Figure 6-4 B1-B3), thus 
confirming that 0.2% adenine feeding needs to be followed by 0.2% adenine + 1.8% P 
feeding as described in literature. Control group mice also did not present any calcification 
throughout the length of the study, as was expected (Figure 6-4 C1-C3). 3D models 
fabricated using the CTAn software allowed us to color and visualize aortic calcification 
in the Ade+hP group providing another in vivo assessment tool to track disease progression 
(Figure 6-5). 
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Figure 6-4: Representative images from in vivo 3D micro-computed tomography (Micro 
CT) scanning and reconstruction. Coronal, sagittal and traverse sections from all the three 
groups of mice are shown – Ade+hP (A1-A3), Ade+nP (B1-B3) and Control (C1-C3). 
Calcification visualized on the reconstructed scans of Ade+hP is illustrated by red dotted 
lines, arrows and circle in coronal, sagittal and transverse scan images respectively. (n=6 
animals per group). 
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Figure 6-5: 3D modeling of reconstructed mouse abdominal micro CT scans. Bone tissue 
is pictured in white while possible aortic calcification in the Ade+hP group is colored in 
red. (n=6 animals per group). Scale bar = 400µm. 
 
 Ultrasound imaging to monitor aortic calcification 
 Local PWV values were calculated using the distance between the two points in a 
region of aorta divided by the transit time (Figure 6-6). Baseline PWVs in the three groups 
did not differ from each other as was expected. No significant differences were seen in the 
local PWVs at the 4 week feeding time point as well. However, following 4 weeks of high 
P diet feeding, PWVs in the Ade+hP group (2.41±0.53 ms-1) were significantly higher than 
in the Ade+nP (1.77±0.21 ms-1) and control groups (1.61±0.16 ms-1) (Figure 6-7 A-B).   
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Figure 6–6: Local Pulse Wave Velocity (PWV) calculated as the distance traveled by the 
pulse wave over transit time. (A) Colored Doppler and (B) Pulse-wave Doppler images 
showing calculations of distance traveled and transit times respectively.  
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Figure 6-7: Local PWV in the abdominal aortas of the three groups of mice. (A) Mean 
Local PWV (ms-1) of Ade+hP, Ade+nP and Control groups at 0, 28 and 56 days of feeding. 
(B) PWV (ms-1) of all the mice from Ade+hP, Ade+Np, and Control groups at 0, 28, and 
56day time points. (n=6 animals per group) (*, p<0.05, One –way ANOVA with Tukey’s 
HSD). 
 
 
113 
 
 Targeting of ELN-DiR-NPs to calcified regions of aortas 
 Elastin antibody conjugated and DiR dye loaded NPs (ELN-DiR-NPs) were 
injected through tail veins of mice at the end of customized diet feeding. The NPs targeted 
the calcified and degraded aortic elastic lamina sites within 24 hours while sparing the 
healthy regions of the aorta in 4 out of 6 mice in the Ade+hP fed group injected with ELN-
DiR-NPs (Figure 6-8A a1), corresponding with the regions showing possible calcification 
in both the Micro CT and Ultrasound images. Mice that were fed Ade+nP and control diets 
did not show any targeting of the NPs to the aorta (Figure 6-8A a3, a5). Cross-sections of 
aortas from Ade+hP fed mice show positive signal for Cy7 fluorescence confirming that 
the ELN-DiR-NPs reached the calcified sites and targeted the degraded elastin fiber. No 
fluorescent signal could be detected in aortic cross-sections from the remaining groups of 
mice (Figure 6-8B).  
 Whole-mount aorta Alizarin Red staining 
 Images of whole mice aortas stained with alizarin red S and pictured on a 
stereomicroscope show bright red spots for calcium on the aortas from the Ade+hP diet 
group at the same regions where targeting was seen on the DiR fluorescence imaging 
(Figure 6-8A a2). This indicates that the elastin in these aortic regions was degraded and 
calcium was deposited, while the healthy regions did not show any staining for alizarin red. 
No such bright stain spots were seen in aortas from either the Ade+nP fed group of mice 
or control mice (Figure 6-8A a4, a6). 
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Figure 6-8: Targeting of ELN-DiR-NPs and accumulation around calcified sites of the 
aortas in Ade+hP mice. (A) DiR fluorescence as detected on iVIS Lumina imaging system 
and whole-mount aorta alizarin red staining to indicate calcification. (B) Cross-sections of 
aortas showing accumulation of ELN-DiR-NPs visualized by Cy7 fluorescence. (n=6 
animals per group). Scale bar = 400µm. 
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 Histological analysis of aortic cross-sections 
 Representative histological sections of the aortas showed the presence of 
calcification in the alizarin red-stained sections of Ade+hP fed mice (Figure 6-9 A). Black 
deposits of calcium were observed under von Kossa staining (Figure 6-9 D), and elastin 
fiber in the corresponding areas was damaged as shown by the VVG stain and Luna stain 
images (Figure 6–9 G, J). On the other hand, calcification was totally absent in the Ade+nP 
group (Figure 6-9 B, E, H, K) and control-diet fed mice aortic cross-sections. VVG and 
Luna stain images from these two groups of mice showed that the elastin fiber remained 
intact (Figure 6-9 C, F, I, L).   
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Figure 6-9: Representative histological images of aortic cross-sections from Ade+hP diet, 
Ade+nP diet and control diet-fed mice (n=6 per group). Alizarin Red S and von Kossa 
staining showing calcification and calcium deposition in the media layer of Ade+hP mice. 
Elastin fiber disruption and breakage as observed in VVG- and Luna- stained sections. 
(n=6 animals per group), Scale bar = 100µm. 
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 Immunohistochemistry for VSMC-Osteogenic phenotypic switch 
 We performed immunohistochemistry to probe VSMC cell status after customized 
diet feeding. Comparisons were made between the three groups – Ade+hP, Ade+nP, and 
control – for expression of smooth muscle markers and osteogenic proteins. Staining for 
SMC Actin showed that its expression is more or less uniform across the three treatment 
groups, with somewhat lesser staining in Ade+hP and Ade+nP groups (Figure 6-10 A-C). 
IHC staining for another smooth muscle marker, Myosin heavy chain 11 (SMMHC) did 
not elicit any presence of the protein in both the adenine groups. However, its presence was 
detected in the control group (Figure 6-10 D-F).  
 In addition to smooth muscle markers, we wanted to observe possible expression 
of osteogenic markers in mice aortas. Specifically, we stained for RUNX-2 and BMP-2. 
RUNX-2 expression in greatest in Ade+hP group, while it was not detected in either the 
Ade+nP or control group (Figure 6-10 G-I). Similarly, the second osteogenic marker, 
BMP-2, was also clearly identified in the Ade+hP group. BMP-2 staining was completely 
absent in Ade+nP and control groups (Figure 6-10 J-L). Overall, IHC points towards the 
phenotypic transformation of VSMCs in mice aortas from the Ade+hP group, as is 
expected due to calcification.  
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Figure 6-10: Immunohistochemistry for possible VSMC phenotypic transition to 
osteoblast-like cells. Expression of two smooth muscle markers, SMC Actin, and SMC 
Myosin is shown. Osteogenic markers RUNX-2 and BMP-2 are also shown in 
representative micrographs pictured from all three groups of mice. (n=6 per group). (Brown 
= DAB staining for SMC Actin and SMC Myosin, Red = NovaRed stain for RUNX-2 and 
BMP-2, Blue = nuclei). Scale bar = 100 µm. 
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 Differential gene expression in isolated aortas 
 Among 22,206 analyzed gene expressions analyzed using the Mouse Clariom S 
Array, 273 genes showing differential expression between Ade+hP and control groups 
were identified with a cut-off fold change ≥ 2 or ≤ -2, and p < 0.05. Of the 273 genes with 
differential expression, 163 showed up-regulation and 110 genes were down-regulated in 
the Ade+hP group. Several genes known to be involved in calcification such as ALPL, 
BMP2/4. Spp1, RUNX2, MSX2, etc. showed upregulation in the adenine+hP group, but the 
fold change remained insignificant. VSMC-associated genes including Myh11, aSMA, 
Tagln were downregulated but without any statistical significance. 
 
Figure 6-11: Heat map of gene-level whole-transcriptome differential expression 
profiling assay in Ade+hP diet- and control diet-fed groups of mice. (n=3 per group). 
120 
 
 Discussion 
 In the present study, we wanted to establish and validate the adenine-CKD model 
in mice and achieve targeting of ELN-BSA-NPs to diseased (calcified) regions of the aorta 
for further usage in calcification reversal and vascular health studies. Although we have 
shown earlier that removal of elastin-specific vascular calcification by EDTA chelation 
therapy is achieved in rat models of CaCl2 injury [259]  and adenine model of CKD [281], 
it is unclear if this removal is permanent and restores vascular homeostasis.  
 As with rats, established techniques to induced renal failure and its complications 
in mice are mostly dependent on surgical intervention and/or transgenic manipulation [145, 
162, 260, 282]. The adenine-induced CKD animal model again provides a viable 
alternative due to its easy relative ease in implementation. However, the adenine model 
does not consistently develop VC over time [262], owing partly due to the commonly used 
C57BL/6J strain being quite tolerant of ectopic calcification [283].  A similar dosage of 
adenine recommended in rats is next to impossible to implement in mice, as this level of 
dosage (0.75% w/w) or even lower can prove lethal to mice within days [277]. Based on 
some recent findings, 0.2% w/w seems to be a suitable dosage of adenine to induced CKD 
in mice of C57BL/6J strain [277, 279].  
 In agreement with multiple reports of a strong association between VC and 
phosphorus loading [275, 284-286], Tani et al. recently developed an adenine-based model 
of CKD capable of producing MAC, without any genetic manipulations, surgical 
interventions, or drug administration [287]. However, in our experience, reproducing their 
model of adenine-based CKD and VC proved moderately successful. We surmise that this 
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is due to inherent biological variation among animals themselves or the genetic strain used. 
Recently, Yoshida et al. reported DBA/2 mice to be a suitable mouse model for the study 
of MAC in CKD than C57BL/6J mice, which are thought to be calcification resistant [288]. 
Even so, during the course of this study, a few other studies have reported successful 
induction of MAC in C57BL/6 mice via modifications of their own, either by altering the 
route of adenine administration [289] or modification to the existing recommendations of 
adenine feeding [290]. Based on our understanding of this model, the consistency and 
severity of VC in this model still prove elusive. Further studies need to be pursued with 
appropriate modifications and improvements to this model to attain a robust and stable 
induction of MAC. 
 In our study with modifications to the model proposed by Tani et al., we 
investigated targeting of NPs conjugated with elastin antibody to sites of aortic 
calcification, developed in vivo imaging methodologies to monitor the onset and progress 
of VC and further validated the model by probing VSMC transdifferentation and their 
global gene expression profiles. A major hindrance of using noninvasive in vivo models of 
vascular VC is the difficulty in monitoring the onset and progress of the disease. In our 
study, we used high-resolution micro CT scanning and high-frequency ultrasound imaging 
to produce images that can be used to analyze and quantify VC in the adenine-model of 
CKD.  Longitudinal micro CT scanning allowed us to detect the onset and presence of VC 
in Ade+hP mice without the extended use of radiation or without injecting any contrast 
agents. So far, studies to detect aortic calcium content using micro CT feature the use of 
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contrast agents [291, 292] or employ transgenic mice models that take as long as 6-12 
months to develop quantifiable calcification in the aortic tree [293, 294].   
 We measured PWV of the infrarenal regions of the aorta non-invasively as a 
function of aortic distance and the transit time from Color-Doppler and Pulse-wave 
Doppler-mode view windows to determine local aortic stiffness [295, 296]. This method 
of PWV measurement is used ubiquitously in pre-clinical research, although it is used over 
a larger length typically between the carotid and femoral arteries [297, 298]. As it happens 
for carotid-femoral PWV evaluation in humans, this assessment is influenced by an error 
in distance measurement even more so in mice due to the distance being ~10 times smaller 
[299]. However, alternative methods to measure PWV are invasive with catheter-tip 
pressure transducers placed in two different arteries to measure intra-arterial pressure and 
transit times. An evident disadvantage with this approach is that the invasive procedure 
may result in the death of the animal, which, in most cases, has to be dissected for exact 
spatial distance measurement [299-301]. Our use of the simple, non-invasive method to 
measure regional PWV gave us values ~2 ms-1, which are in agreement with literature [296, 
302]. Green-LaGrange circumferential strain calculated from M-mode images serves to 
further corroborate aortic stiffness caused due to VC in mice. 
 We demonstrated the reproducibility of our targeted nanoparticle delivery system 
in this mouse model of adenine-CKD induced vascular calcification. Similar to our results 
with rats, we observed no fluorescence emanating from aortas of control-diet fed mice or 
in mice fed with 0.2% diet and normal levels of P (0.8%). When the P content in the 0.2% 
adenine diet was switched up to 1.8% after initial induction of renal failure, the aortas 
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clearly showed targeting of our NPs carrying DiR. Even in these mice, healthy regions of 
the aorta with uncalcified and undamaged elastin did not show any detectable fluorescence, 
confirming that the elastin antibody conjugated NPs only target diseased regions of the 
aortas. Cross-sections of these aortas further validate our findings by ratifying that the 
ELN-DiR-NPs infiltrate the medial layers of the diseased aorta through the vasa vasorum. 
Our targeted delivery system can, therefore, be used to deliver any therapeutic to damaged 
elastin and calcified sites in these mice.    
 Micrographs taken from histological staining of mouse aortas show clear evidence 
of MAC exclusively. Elastic fiber layers in these calcified areas appeared to be disrupted 
and broken around areas of calcium deposition, which is a characteristic feature of MAC. 
Immunohistochemical staining for presence of common smooth muscle markers, α-SMC 
actin, and SMMHC, was done to observe phenotypic alteration in VSMCs. α-SMC actin 
was found to be expressed evenly across the three groups, whereas SMMHC staining was 
lower in both the adenine-fed groups. Parallelly, we also detected positive staining for both 
osteogenic markers, RUNX-2 and BMP-2, in the Ade+hP group. No expression for either 
was seen in either the Ade+nP group or control group. This suggests a phenotypic switch 
of VSMCs associated with calcification in the Ade+hP group. Differential gene expression 
profiles obtained by Clariom S Arrays showed that 163 genes were upregulated in the 
Ade+hP group. Genes known to be involved in calcification and VSMC phenotypic switch 
to osteoblast-like phenotype such as ALPL, BMP2/4, Spp1, Igf1, MSX2, RUNX2, etc., 
although upregulated, did not show significant fold change difference. Genes associated 
with VSMCs namely Myh11, aSMA, Tagln, and others showed slight downregulated 
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compared to the control group. However, the increase or decrease in expression of both 
osteogenic- and VSMC-associated genes were not statistically significant. Further 
experiments with higher sample size and analyses are needed to draw more informative 
conclusions from gene expression profiles.  
 In conclusion, we were able to establish the adenine-induced CKD model of 
calcification in a commonly used C57BL/6J strain of mice. Usage of small animal imaging 
techniques viz., high-resolution microCT scanning, and high-frequency ultrasound 
imaging help us to monitor the progress of VC and gauge aortic stiffness parameters in 
these mice in vivo. We successfully demonstrated that our NP delivery system is able to 
target diseased regions in the aortas of mice with calcified aortas. Further validation of the 
model confirms that there is a transdifferentation of VSMCs to an osteogenic phenotype 
happening in the event of VC in the aorta. This model of adenine-induced CKD model of 
VC will allow us to test our targeted chelation therapy with EDTA NPs through monitoring 
and quantification of calcification in vivo and to investigate whether its reversal will result 
in restoration of healthy VSMC status, thus improving vascular function.   
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7 SPECIFIC AIM 4 
 
TO DEVELOP AN EX VIVO PORCINE CAROTID ARTERY ORGAN CULTURE 
MODEL OF VASCULAR CALCIFICATION FOR EVALUATING WHETHER 
TREATMENT WITH EDTA LOADED NANOPARTICLES CONJUGATED WITH 
AN ANTI-ELASTIN ANTIBODY ELIMINATES CALCIFICATION AND 
REVERTS VSMCs TO THEIR NORMAL PHENOTYPE 
 
 Introduction 
 Vascular calcification (VC) is now considered an active and complex process 
resembling developmental skeletal formation. In addition to key events required for 
initiation and propagation of VC, such as loss of inhibitor function, upsurge of calcification 
promoters, development of calcifiable extracellular matrix (ECM) with degradation of 
elastin laminae due to inflammatory enzymes, and osteogenic differentiation of vascular 
smooth muscle cells (VSMCs) accompanying apoptosis and vesicle release.  The latter two 
are key mechanisms that may occur simultaneously. There is a longstanding debate 
regarding which process occurs first, whether adoption of an osteoblast-like phenotype by 
VSMCs leads to or results from elastin damage and calcification [303]. We have evidence 
to believe that elastin degradation and mineralization occurs first, which triggers VSMC-
osteoblast-like cell phenotypic shift [273, 274]. We further hypothesize that 
demineralization of calcified arteries promotes restoration of homeostasis. 
 Calcifying vascular cells have been known to share properties with bone, including 
higher alkaline phosphatase (ALP) activity, osteocalcin (OCN) and osteopontin (OPN) 
expression and increased presence of the bone morphogenic protein (BMP) family [304, 
305]. A number of studies have focused on understanding the underlying process of VC 
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through in vitro models of primary cell lines from mice [306], bovine [307], and human 
cells [275, 308]. Usage of monocultures allows for better control of initial experimental 
conditions to improve detection accuracy. However, morphological variation has been 
noted at higher passage numbers, and beyond that, gene phenotype of VSMCs is altered. 
Moreover, a 2D cell culture cannot correctly examine the influence of cell-cell interaction.  
 Therefore, in this present aim, we hypothesize that an organ culture model would 
provide useful information to bridge the gap between monolayer cultures and animal 
models in vogue. Since our terminal goal is to transition our EDTA chelation therapy from 
present small animal models to human application, we presumed that an ex vivo organ 
culture from a larger animal would provide a feasible culture condition for assessment of 
VC, and VSMC cell status before and after demineralization. Here, we propose a porcine 
carotid artery organ culture model of VC under Pi-stimulation.   
 Materials and Methods 
 Isolation and collection of porcine carotid arteries 
Fresh porcine carotid arteries were harvested from female domestic crossbred pigs with a 
Yorkshire background in Godley-Snell Research Center (Clemson, SC) for this study. All 
animals were 3-4 months old and weighed 35-45 kg. After the pigs were euthanized using 
commercial euthanasia solution, the thyroid cartilage was located. A 10 cm incision was 
made 3 cm laterally to the thyroid cartilage using a 10-blade scalpel, extending 5 cm 
superiorly to the thyroid cartilage and 5 cm inferiorly to the thyroid cartilage. Curved Mayo 
scissors were used to dissect through the underlying fascia and expose the sternocephalic 
muscle. The sternocephalic muscle was retracted to expose the internal and external jugular 
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veins, the common carotid artery, and the vagus nerve. The carotid sheath was dissected 
using a 10-blade scalpel, and the carotid artery was isolated and removed using surgical 
scissors. Following excision, the arteries were placed in sterile Moscona’s solution (8 g 
NaCl, 0.2 g KCl, 1 g NaHCO3, 1.7 g glucose, 0.005 g NaH2PO4 in 1 L DI water; pH 7.2) 
on ice and transported back to the lab. 
 Organ culture of porcine carotid arteries 
 A day before tissue collection, under sterile conditions, the bottom surface of each 
well in 12 well plates was coated with 2% agarose. Once the agarose hardened, sterile basal 
medium was added to each well (DMEM with 4500 mg/mL glucose), and well plates were 
incubated at 37°C overnight to equilibrate the agarose. On the day of tissue harvest, the old 
medium was replaced with fresh basal medium, and equilibration was continued until the 
tissues were ready. The collected carotid arteries were washed well in cold, sterile PBS 
supplemented with 1-3% Penicillin/Streptomycin, to remove remnants of blood, and the 
surrounding tissues were carefully cleaned with sterile, blunt forceps. Carotid arteries were 
then cut into rings of 1-2 mm in length and washed in cold, sterile PBS. Artery rings were 
placed individually in the pre-incubated and pre-equilibrated 12 well plates. Basal medium 
was now replaced with complete culture medium (DMEM with 4500 mg/mL glucose 
supplemented with 15% FBS, 1% Penicillin/Streptomycin). To induce calcification, Pi 
(Na2H2PO4/NaH2PO4 at pH 7.4) was added the supplemented DMEM at a high 
concentration of 2.6mM in half of the total wells. The culture medium, both control and 
calcification media, was changed every 2 days. The culture went on for 1, 3, and 7 days 
followed by treatment with n=5 for each time point. An example well plate is outlined in 
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Figure 7-1. Tissues were cultured in individual well plates for histology, protein, and RNA 
isolation at each time point, respectively. 
 
 
 
Figure 7-1: Sample well plate of porcine carotid artery organ culture. Blue designates 
wells with control culture medium. Wells containing medium supplemented with Pi to 
induce calcification are pictured in red. (n=5 per time point per study).  
 
 Treatment of porcine carotid rings with EDTA NPs for ex vivo 
chelation therapy 
 Following induction of calcification at Day 7, carotid artery rings were treated with 
nanoparticles (NPs) loaded with EDTA and conjugated with an anti-elastin antibody (ELN-
EDTA-NPs) to examine for possible reversal of calcification. After aspirating media and 
washing the tissues with sterile PBS, NPs were applied directly on the tissue rings (at a 
final concentration of 10 mg EDTA per well) using a micropipette and allowed to conjugate 
for a short time.  Media was replenished immediately afterwards to continue the culture. 
NPs without any EDTA loaded, but conjugated with the anti-elastin antibody were used 
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for non-EDTA control group (ELN-Blank-NPs). A third of group of wells were not treated 
with any NPs to act as non-treatment controls. The tissues were treated as described above 
for two times every 3 days over one week.  
 Histological staining of carotid artery rings 
 At Day 1, 3 and 7, the carotid artery rings consigned to undergo histological 
analyses were taken out from their respective well plates and fixed in 10% neutral buffered 
formalin for 24 hours. Following processing for removal of formalin, the rings were 
embedded in paraffin and sectioned at 6µm thickness and stained with the following 
histological stains for tissue morphology – Hematoxylin & Eosin (H&E), Verhoeff von 
Geison (VVG), Alizarin Red S, von Kossa, Luna staining for elastin fibers.  
 Immunohistochemical analyses for expression of osteogenic markers 
 Briefly, rehydrated paraffin sections (5 μm) were exposed to a boiling water bath 
in a pressure cooker for 10 minutes with citrate buffer (10 mM Sodium Citrate, 0.05% 
Tween 20, pH 6.0) for heat-induced unmasking of antigens.  Endogenous peroxidases were 
quenched with 3% hydrogen peroxide. Tissue sections were incubated in normal serum for 
1hr at RT to block out non-specific binding. Primary Antibodies against were applied 
overnight at 4°C against Alpha smooth muscle actin (ACTA2, or SMC actin) (Novus 
Biologicals, Centennial, CO), Smooth Muscle Myosin Heavy Chain (MYH11, or 
SMMHC), Runt-related transcription factor (RUNX-2) (Santa Cruz Biotechnology, Inc., 
Dallas, TX), Bone morphogenic factor-2 (BMP-2). Following primary antibody 
incubation, relevant secondary antibodies were applied, and signal was enhanced by ABC 
method (Vector, Burlingame, CA). Slides were visualized by either 3,3´-Diaminobenzidine 
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(DAB) or NovaRed peroxidase substrate chromogens (Vector, Burlingame, CA) followed 
by a light hematoxylin counterstaining prior to mounting.  
 Quantification of calcium in tissue rings 
 Following being harvested and washed with PBS, the aortic rings were treated with 
0.6 N HCl overnight at 4°C to decalcify and release bound Ca into the supernatant. Dissolve 
calcium in the supernatants was determined by the o-Cresolphthalein method using a 
commercially available kit (Abcam Inc., Cambridge, MA). This method is based on Ca 
reacting with o-Cresolphthalein complexone in an alkaline solution. Ca concentrations 
were reported after being normalized to dry weights. 
 Total protein extraction from carotid cultures  
 Carotid artery rings were collected at each time point for protein extraction, snap-
frozen, and stored at -80°C until extraction. Frozen tissue rings were pulverized with pre-
cooled mortar and pestle and placed in pre-cooled 1.5mL centrifuge tubes containing 
600µL RIPA buffer (23 mM Tris-HCl pH 7.6, 150 mM NaCl, 5 mM EDTA, 1% Triton X-
100, 1% sodium deoxycholate, 0.1% SDS substituted with protease inhibitors at the time 
of use). Vortex well and homogenize the tissue completely using probe sonication. The 
tubes were then shaken on ice for approximately 3 hours, and proteins were extracted by 
centrifugation @12000rpm at 4°C for 20 minutes. The resulting supernatants were 
carefully transferred to fresh, precooled 1.5mL tubes using a micropipette and stored at -
20°C for further analyses. BCA protein assay was performed on the final samples to 
determine the protein concentration.  
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 Western Blotting 
 Samples containing equal amounts of protein, as measured from protein 
quantification, were mixed with 4X reducing buffer containing β-mercaptoethanol, boiled 
down 5 minutes and cooled. They were then subjected to sodium dodecyl sulfate-
polyacrylamide electrophoresis with Tris/Glycine denaturing running buffer (25 mM Tris, 
192 mM Glycine, 0.1% SDS) for 50 minutes at 200V on 4-15% Mini-Protean TGX precast 
gels (BioRad Laboratories Inc., Herculus, CA).  The gels were subsequently transferred to 
pre-conditioned polyvinyl fluoride (PVDF) membrane. The transfer lasted for 50 minutes 
at 100V in a tank system on ice, using Tris/Glycine transfer buffer (25 mM Tris, 192 mM 
Glycine, 20% methanol). After washing with TBS and blocking for 1 hour at RT using 
10% non-fat dry milk in TBS, the membrane was washed in TBST (0.05% Tween in TBS) 
3 times for 5 minutes each. The membrane was then incubated overnight at 4°C with 
primary antibodies in 2% dry milk in TBST. The following primary antibodies were used: 
Alpha smooth muscle actin (ACTA2, or SMC actin, 1:10000) (Novus Biologicals, 
Centennial, CO), Smooth Muscle Myosin Heavy Chain (MYH11, or SMMHC, 1:3000) 
(Proteintech Group Inc., Rosemont, IL), Runt-related transcription factor (RUNX-2, 1:500) 
(Santa Cruz Biotechnology Inc., Dallas, TX), and Bone morphogenic factor-2 (BMP-2, 
1:2000) (Proteintech Group Inc., Rosemont, IL). GAPDH (1:1500) (Proteintech Group 
Inc., Rosemont, IL) and β-actin (1:1000) (Santa Cruz Biotechnology Inc., Dallas, TX). The 
next day, the membrane was washed 5 times for 10 minutes in TBST to remove the 
unbound primary antibody and incubated with an appropriate HRP-conjugated secondary 
antibody (1:20000) in 2% dry milk in TBST for 1 hr at RT. After washing with TBST for 
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3 times 10 minutes each time, the membrane was developing using Clarity Western ECL 
Substrate (BioRad Laboratories Inc., Herculus, CA) for 5 minutes. Membranes were then 
imaged using Chemi Doc It2 imaging system (UVP) at different exposure times for 
individual proteins. Densitometry analysis was performed using Image J software for 
quantification. 
 
 Results 
 Histology of porcine carotid artery rings  
 Hematoxylin & Eosin staining of formalin-fixed and paraffin-embedded carotid 
ring sections show appreciable staining for nuclei until Day 3 of the organ culture in the 
calcified group alluding to cellular presence. Only on Day 7, there is a noticeable decrease 
in nuclear staining (Figure 7-2 B-D). Images from the control group suggest that the cells 
are thriving throughout the duration (Figure 7-2 A). Luna stain and VVG stain were used 
to observe elastin fiber morphology.  There is no discernible damage to elastin seen in the 
calcified group in any of the Day 1, Day 3 or Day 7-time points, either on the Luna stained 
sections (Figure 7-2 F-H) or VVG sections (Figure 7-2 J-L). As expected, intact elastin 
fiber was identified in the control group (Figure 7-2 E, I).  
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Figure 7-2: Digital micrographs of H&E, Luna, and VVG staining on porcine carotid 
rings. (A-D) H&E staining shows. (E-H) Luna stain illustrates intact elastin fiber structure 
with no obvious damage. (I-L) VVG Stain for elastin fiber confirms observations made on 
Luna stain images. (n=5 per time point per group). Scale bar = 200 µm.  
 
 
 
 Evaluation of calcification of the carotid arteries 
 Alizarin Red S staining was performed to evaluate calcium deposition. Following 
incubation of the carotid arteries with calcification medium, faint deposition of calcium is 
observed as early as Day 1 of the organ culture (Figure 7-3 B). 
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Figure 7-3: Evaluation of calcification by histological staining of carotid artery rings. 
Representative images of calcification in porcine carotid artery cross-sections as pictured 
by Alizarin Red S stain (A-D) and von Kossa Stain (E-G) (n=5 per time point per group). 
Scale bar = 200 µm. 
 
Calcium deposition increases as the culture progresses at Day 3, and by Day 7, heavy 
calcification of the carotids was seen microscopically (Figure 7-3 C-D). von Kossa staining 
confirms the presence of calcium deposits with increasing deposition from Day 1 through 
Day 7 (Figure 7-3 F-H). No calcification or calcium deposits are observed in the carotid 
arteries incubated with control medium (Figure 7-3 A, E). 
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 Immunohistochemistry for smooth muscle cell apoptosis and smooth 
muscle marker expression 
 Immunohistochemistry for Caspase-3 shows considerable expression of the 
apoptotic protein across control and calcified groups.  At Day 1, 3, and 7 in the calcified 
arteries, Caspase-3 is present in all the three layers of the arterial wall (Figure 7-4 A-D).  
Staining for SMC actin is comparable in the control group, and at all the three-time points 
in calcified arteries, indicating that there may not be a reduced expression, as expected, 
with increasing calcification (Figure 7-4 E-H). SMMHC was fairly well expressed in the 
control group. Calcified group shows a negligible signal for SMMHC on Day 1 and 3, 
whereas its expression was detected at Day 7 (Figure 7-4 I-L). Overall, smooth muscle cell 
apoptosis is consistent in both control and calcified arteries; Expression of SMC actin was 
not found to decrease over time with increased deposition of Ca in the calcified arteries. 
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Figure 7-4: Immunohistochemical staining for smooth muscle apoptosis and expression of 
smooth muscle markers. Representative images of calcification in porcine carotid artery 
cross-sections from Caspase-3 (A-D), ACTA2 (E-H), and SMMHC (I-L) staining. (n=5 
per time point per group). (Brown = DAB, purple = nuclei). Scale bar = 200 µm. 
 
 
 Immunohistochemistry for expression of osteogenic cell markers  
 Following analysis of smooth muscle cell apoptosis and expression of smooth 
muscle cell markers, we wanted to observe for possible upregulation in osteogenic cell 
markers. As seen in Figure 7-5, there was very sparse, if any, expression of both RUNX-2 
(B-D) and BMP-2 (F-H) in the calcified group at Day 1, 3 and 7-time points. Only on Day 
7, RUNX-2 could be detected in calcified group. Control group did not show any staining 
for the two osteogenic markers, which was expected (A-E).  
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 Based on observations made with IHC staining, VSMCs in the carotid artery 
cultures seem to undergo apoptosis both in the control and calcified groups. There was no 
significant reduction of smooth muscle cell marker expression or upturn in osteogenic 
marker expression in the calcified group. 
 
Figure 7-5: Immunohistochemical staining for osteogenic markers – RUNX2 and BMP2. 
Representative micrographs of IHC staining for RUNX-2 (A-D), and BMP-2 (E-H) in 
control and calcified groups. (n=5 per time point per group). (Red = NovaRed, purple = 
nuclei). Scale bar = 200 µm. 
 
  
   
 Western blot analysis for smooth muscle and osteogenic markers 
 Western blotting was used to check for expression of smooth muscle- and 
osteogenic- markers on total protein isolated from both the groups of carotid artery rings. 
α-SMA expression was normalized to GADPH housekeeping gene, and β-actin was used 
to show relative SM-MHC expression. At Day 1 and Day 7-time points of culture, no 
significant increase or decrease was observed in the expression of the two smooth muscle 
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proteins in the calcified group when compared to controls (Figure 7-6), consolidating the 
observations made with immunohistochemistry.  At any of the time points, no bands could 
be detected for either of the two osteogenic markers. Both RUNX-2 and BMP-2 did not 
show any expression in control and calcified groups (Figure 7-7). 
 
Figure 7-6: Western blots for smooth muscle cell markers in control and calcified carotid 
artery rings. (A, B) α-SMA expression in control and calcified carotid aortic rings. No 
significant difference is seen in expression at either Day 1 or Day 7-time points. (C, D) 
SM-MYH expression in control and calcified carotids. As with α-SMA, there was no 
statistically significant difference in expression at both time points. (n=4 per group per time 
point) (White columns: control group, black columns: calcified group). 
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Figure 7-7: Images taken after western blotting for osteogenic markers in control and 
calcified groups. No expression could be detected for the two osteogenic markers tested – 
RUNX-2 and BMP-2 – at any time point in either control or calcified carotid rings. (n=4 
per time point per group). (Red arrow indicates positive control for RUNX-2; white arrow 
shows protein ladder). 
 
 
 Reversal of Pi-induced calcification with EDTA-loaded NP treatment 
 Treatment with ELN-EDTA-NPs moderately reversed calcification induced by 
supplementation with Pi. Alizarin red staining of carotid artery rings following treatment 
shows modest reversal of calcification in the ELN-EDTA-NPs group while bright red 
calcified areas persevered in the ELN-Blank-NPs group and the untreated group (Figure 7-
8 A-C). Similar results were witnessed with von Kossa staining, with ELN-EDTA-NPs 
staining least for Ca deposits where as both the ELN-Blank-NPs group and untreated 
groups had extensive staining (Figure 7-8 D-F). Tissue rings were decalcified by incubation 
in 0.6N HCl and Ca in the supernatants was quantified using o-Cresolphthalein 
complexone method for detection of Ca. Quantified Ca was normalized to dry weights of 
the tissues with ELN-EDTA-NPs group having mean quantified Ca values of 0.97±0.30 
µg/mg of dry weight. Ca values in ELN-Blank-NPs and untreated groups remained at 
1.39±0.09 and 1.42±0.34 µg/mg of dry weight of tissue respectively. It is pertinent to note 
here that not all the tissues in ELN-EDTA-NPs showed reversal of calcification and the 
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difference remained statistically insignificant (Figure 7-9), probably due to the small 
number of samples tested (n=3). 
 
Figure 7-8: Representative histological images of carotid artery rings depicting 
calcification after treatment. ELN-EDTA-NPs show reasonable reversal of calcification 
while persisting in ELN-Blank-NPs and untreated groups. (n=3 per group) Scale bar = 200 
µm. 
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Figure 7-9: Quantification of Ca by o-Cresolphthalein complexone method following 
treatment. ELN-EDTA-NPs suggest removal of calcification in 2 out of 3 tissue samples 
used. ELN-Blank-NPs and untreated groups have comparatively higher levels of Ca. (n=3 
per group).  
 
 
 Discussion 
 In the present study, we utilized the well-known Pi-induced model of calcification 
in organ culture of porcine carotid arteries for the first time. This experimental model of 
carotid artery culture is relatively simple and easy and cuts down the time to thoroughly 
evaluate the process of induction and reversal of VC.   
 We followed an ex vivo organ culture model described in previous reports [309] to 
generate a high-phosphorus-induced VC [310-313]. Many such studies report that a 
concentration of 2.6-3.0 mM Pi in the culture media as it produces a degree of calcification 
easy to detect through examination under microscopy. However, these studies utilize 
VSMCs from humans, rats, and mice and aortic rings from rats and mice for their culture 
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studies. For our study, we used porcine carotid arteries harvested fresh from swines at the 
local animal research facility. Pi-induced calcification has not been studied in porcine 
artery cultures hitherto, and we believe this will serve as an ideal model to explore VC and 
chelation therapy, towards larger animal studies in vivo. 
 Following exposure to extracellular Pi in the media, carotid artery rings undergo 
time-dependent calcific deposition with increasing deposition up to 7 days in culture, as 
reported in similar studies with other tissues mentioned above. Though, no accompanying 
elastin fiber degradation or destruction was readily apparent in either Luna stained sections 
or VVG staining [314, 315]. Beyond 7 days, there was no apparent increase in calcification 
under microscopic observations on histological stains (data not shown). Hence, we chose 
the Day 7-time point for our reversal experiments.  
 Next, evaluated VSMCs for possible reprogramming into osteoblast-like cells 
through immunohistochemistry, western blotting, and gene expression analyses. Cultured 
SMCs have long been known to be capable of calcifying and expressing osteogenic 
phenotypes when exposed to high levels of Pi [95, 309, 316, 317]. In our assessment for 
phenotypic change of VSMCs into osteoblast-like cells, we found no upregulation of 
RUNX-2 and BMP-2, both markers are known to be expressed by calcifying vascular cells. 
IHC staining for the two osteogenic markers does not show any enhanced staining in 
calcified carotid rings. While VSMCs in cultured rings show expression of the apoptotic 
marker Caspase-3 [318], its presence is universal amongst control and calcified groups. 
Simultaneously, there is no loss of smooth muscle cell markers, α-SMC actin, and 
SMMHC, with time-dependent increase in calcium deposition.  
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 Immunoblot analyses for increased protein expression of RUNX-2 and BMP-2 
showed no detection for either of the two osteogenic markers in the calcified group, on Day 
1 or Day 7-time points. Even after repeated experiments with different concentrations of 
primary antibodies and higher quantities of total proteins loaded for gel electrophoresis, no 
bands could be visualized. Concomitantly, expression of α-SMC actin and SMMHC 
remained fairly constant over the 7-day time period with no statistically significant 
difference between the control and calcified groups. Put together, our data with IHC and 
WB reveals that calcification of the carotid artery rings in this setting maybe due to passive 
mineralization and does not involve any cellular responses.  
 We further assessed whether treatment with EDTA-loaded NPs conjugated with an 
anti-elastin antibody could reverse the Pi-induced calcification in carotid tissue rings. We 
applied EDTA-loaded NPs at a final dosage of 10 mg EDTA/well, twice over a period of 
one week.  Histological staining with alizarin red and von Kossa stains to spot calcification 
following treatment suggest that there is some degree of reversal of calcification with ELN-
EDTA-NPs, while calcification persisted in the tissue sections from ELN-Blank-NPs and 
untreated groups. To measure the Ca present in tissues after treatment, we decalcified the 
carotid rings by placing them in 0.6N HCl [319] and determined the Ca released into the 
supernatant using the o-Cresolphthalein method. The observations we made with histology 
were corroborated with quantified Ca values being noticeably lower in the ELN-EDTA-
NPs group compared to the others. However, out of the three tissue samples used to analyze 
reversal of calcification, only two show lessened calcium. ELN-EDTA-NPs show 
promising results, but the change is not significant. This observation could have been due 
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to the small number of samples used (n=3), and the results did not reach statistical 
significance. To substantiate this hypothesis, a pilot study with increasing amounts of 
EDTA directly added to the media yielded no removal of calcification.  Further, the dosage 
of ELN-EDTA-NPs at 10mg/well may not have been sufficient to achieve complete 
reversal. Higher magnitudes of EDTA targeted to calcific deposits may be needed to 
achieve better removal, although EDTA is known to be cytotoxic.  
 We conclude that exposure to excess Pi concentrations in the culture media resulted 
in time-dependent increase in mineralization of calcium deposits in porcine carotid artery 
rings. Evidence from immunohistochemical staining and western blot analysis for smooth 
muscle and osteogenic markers reveals that there was no significant reduction in expression 
of the former, combined with no increase in bone protein expression at any of the three-
time points. Treatment with ELN-EDTA-NPs moderately removed mineralization from 
calcified tissue rings. At this point, the ex vivo porcine carotid artery organ culture of Pi-
induced VC is not optimized for use in studies to assess effects of EDTA chelation therapy 
on VSMC calcification and transdifferentiation. Further experiments are necessary to 
improve the model to represent the process of active calcification that occurs in vivo.  
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8 CONCLUSIONS AND FUTURE RECOMMENDATIONS 
 
 Conclusions 
 Vascular calcification (VC) is a key pathological feature observed in various forms 
of cardiovascular diseases. It is commonly seen in aging, diabetes, and chronic kidney 
disease (CKD). Elastin-specific medial arterial calcification (MAC) is more commonly 
seen in CKD, and patients with CKD are more prone to die of a cardiovascular event due 
to MAC than fully progress to complete renal failure. Majority of the current treatment 
methods are focused on curtailing the causative factors and preventing calcification. A 
novel therapeutic strategy that stabilizes and eventually reverses calcification is an urgent 
health care need and is of immense value to patients with CKD. We have developed 
nanoparticles that can be targeted to the sites of arterial calcification by using an antibody 
that exclusively recognizes and binds to degraded elastin, a common appearance in 
calcification. Our goal is to load these nanoparticles (NPs) with Ethylene diamine 
tetraacetic acid (EDTA), a well-known chelating agent and deliver EDTA to the calcified 
sites on the aorta to facilitate reversal of mineralization without causing any unpleasant 
side effects.  
 In the first part of this project, we set out to test our targeted EDTA chelation 
therapy in a clinically relevant systemic model of CKD-related calcification. For this, we 
used the well-known rat adenine-induced CKD model of medial calcification. We 
established this model without unexpected mortality, as is usually seen, and fairly evenly 
produced calcification across all animals. Then, we demonstrated the ability of our NPs to 
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target calcified sites on the aortas of these rats. We were able to successfully reverse 
mineralized calcium in vivo by site-specifically delivering EDTA at a dosage ~twenty-fold 
lower than systemic chelation therapies currently in use. This was achieved without causing 
any unwanted side effects, and the animals showed signs of improvement in vascular 
function. 
 Subsequently, we replicated targeting of NPs to calcified sites in a murine model 
of CKD-related calcification. This was accomplished in adenine plus high phosphate 
induced model of CKD and medial calcification. We further wanted to establish ways to 
monitor disease progression in vivo for forthcoming investigations on reversal of 
calcification and its effect on disease outcomes and vascular health. For this, we used small 
animal imaging techniques such as ion micro CT and ultrasound to visualize onset and 
development of calcification. One of our eventual objectives is to explore phenotypic 
changes in VSMCs prior to and after reversal of calcification in vivo. Stringent cell lineage 
tracing studies on VSMCs will be required to probe their fate, and we laid down the first 
step by profiling global gene expression of VSMCs in calcified aortas of the adenine-diet 
fed mice. 
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 Recommendations for future work 
1) Despite the successful use of adenine model to evaluate chelation therapy in 
reversal of MAC, this model presents high biological variability with regards to 
development of robust calcification. In humans, calcification is seen throughout 
the length of the aortic tree, and in heart valves as well. In our experience with 
the adenine model, both in rats and mice, calcification in these animals was 
restricted to infrarenal region of the aorta. Keeping in consideration studies 
showing calcification at various loci on the aorta, we have only had moderate 
success in establishing severe MAC at different sites on the vasculature. 
Additionally, all the animals used in this model do not show calcified deposits; 
only as many as 60% of the animals develop MAC. Put together; it would require 
an unusually high number of animals to investigate and compare treatment 
regimens with acceptable statistical power. It is essential to make further 
adjustments to the model we used, not restricted to dietary alterations, and usage 
of a genetic strain of mice more prone to calcification. 
2) At this time, we do not know if the VSMCs return to their original phenotype 
after reversal of calcification in vivo, or if they undergo apoptosis and are 
repopulated by new SMCs recruited from surrounding cells, pericytes, 
endothelial-mesenchymal transition (EndoMT), or hematopoietic stem cells 
(HSC). Lineage tracing studies need to be performed with tamoxifen-induced Cre 
recombinase mice with dual fluorescence indicator/reporter for SMC, EndoMT, 
HSC, or pericyte origin. 
148 
 
3) The groundbreaking nanoparticle delivery system alone could be used to deliver 
not just chelating agents, but other specific drugs, proteins, or imaging agents to 
the calcified sites, and could open a host of possibilities. For example, the targeted 
delivery system could be utilized to deliver pentagalloyl glucose (PGG) to the 
damaged elastin sites. PGG tightly binds to elastin and blocks its calcium-binding 
sites, while also helping in reduced expression of matrix-degrading enzymes and 
osteogenic proteins, in addition to replenishing elastin fiber deposition. 
4) Patients with CKD need dialysis as their kidney function worsens and GFR falls 
below 15. As mentioned, the long term goal of this project is to translate our 
targeted EDTA chelation to individuals suffering from kidney disease and 
improve their cardiovascular outcomes. It would, therefore, be judicious to 
administer targeted EDTA chelation to the patients at the time of dialysis as a co-
therapy, to avoid repeated incisions. Currently, each dialysis treatment lasts about 
four hours and is done three times per week. At this stage, our NPs are designed 
to release EDTA in a burst release manner over a period of 72 hours. This would 
mean that patients need to be given intravenous injections at a rate of two times 
per week if the targeted EDTA chelation regimen is endorsed. Accordingly, it is 
recommended that further tailoring of the NPs is necessary to ensure that the 
chelating agent is released quicker, within 48-72 hours, to ensure that co-therapy 
with dialysis remains a possibility.  
5) Different mineral phases arise during uremic MAC due to the result of different 
pathological mechanisms involved in their precipitation. Hydroxyapatite 
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[Ca10(PO4)6OH2], a common skeletal mineral was reported in uremic arterial 
calcifications in some studies [320, 321]. In another study, a combination of 
brushite and hydroxyapatite were observed in calcifications of stenotic 
arteriovenous fistulas [322]. A study of uremic calcification in rodents detected 
the presence of whitlockite [(Ca, Mg)3(PO4)2], along with hydroxyapatite [323]. 
Recently, whitlockite was identified in human uremic arterial calcifications. This 
is in contrast to most studies, which so far have reported only hydroxyapatite or 
carbonated apatite in uremic vascular calcifications [322]. It would then be 
imperative to properly characterize the kind of mineral deposition present in the 
calcified aortas of patients with CKD as this would affect the choice of chelating 
agents for dissolution of mineral.  
6) Considering the value of in vivo imaging and monitoring of disease progression 
in impending studies in mice, it would be useful to have another diagnostic tool 
using CT imaging with gold as X-ray contrast. Currently, we relied on CT 
scanning without the use of any contrast agents for improved visibility of 
calcification. Recently, our lab has evinced that gold NPs, combined with the 
elastin targeting approach, can be used to predict the degree of elastin damage 
and rupture potential in AAAs [324]. A quantitative relationship may thus be 
established to correlate elastin damage at calcified sites and corresponding gold 
nanoparticle binding, providing us an additional remarkable visual tool to track 
development of calcification in mice before, and after EDTA chelation therapy.  
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7) Arterial calcification is augmented in metabolic syndrome, type 2, and type 1 
diabetes mellitus, resulting in impaired vessel compliance and function. 
Consequences of MAC in diabetes are impaired hemodynamic regulation and 
increased cardiac post-load; it is a strong predictor of lower-extremity amputation 
and mortality. Patients with type 2 diabetes were at a four-fold increased risk for 
lower-extremity amputation and two-fold enhancement of cardiovascular 
mortality [325, 326]. Use of site-specific chelation therapy for reversal of diabetic 
MAC and improvement in arterial health is thus an attractive prospect.  
8) Our nanoparticle targeting system is a product of several years of successful 
substantiation in various ex vivo and in vivo small animal models. To utilize this 
approach for targeting of damaged elastin in other pathologies such as Marfan 
syndrome, varicose veins, deep vein thrombosis, cutis laxa, Pseudoxanthoma 
elasticum (PXE), etc. can result in fresh drug delivery strategies.  Additionally, 
nanoparticle surfaces could be modified to target established markers to specific 
cancers [327, 328]. 
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